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 1.1. Summary 
 
In the last years new technologies considerably improved the development of vaccines. 
Genomics-based, high throughput techniques contributed significantly to antigen 
identification and selection for many pathogens. However, vaccines consisting of even the 
most carefully selected antigens only are limited in their application, as immunisation with 
such preparations does not always lead to an adequate immune response. Therefore, 
supplementation of vaccines with adjuvants that improve and modulate the immune system is  
desirable. The number of adjuvants licensed for human application is limited. Currently, only 
Alum, MF59 and Virosomes are on the market and only Alum is licensed worldwide.  
IC31® is a novel potent adjuvant composed of the cationic antimicrobial peptide NH2-
KLKLLLLLKLK-COOH (KLK) and the TLR9 agonist oligonucleotide ODN1a 
(poly(dIdC)13).  
In this research project we clarified the molecular mechanisms behind the function of IC31®. 
We demonstrated profound membrane-interacting properties and unique conformational 
transitions of KLK. Interaction of this peptide with various membrane vesicles as well as cells 
altered membrane ultrastructure and cell surface morphology.   
We showed that KLK forms aggregates with ODN1a. Due to charge attraction and 
membrane-interacting properties of KLK, these complexes are readily attracted to cell 
surfaces. We revealed that the presence of KLK considerably increased endocytic uptake of 
ODN1a into dendritic cells. We localized the nucleotide in both early and late endosomes as 
well as the endoplasmic reticulum. Further, we observed ODN1a in TLR9 positive 
compartments while KLK was demonstrated to stay associated with the plasma-membrane. 
Our results made significant contributions to better understanding of the molecular action of 
IC31®. With these contributions IC31® became one of the best understood adjuvants in 
current vaccine research.  
 
 
 1.2. Zusammenfassung 
 
In den letzten Jahren wurde die Entwicklung von Impfstoffen durch neue Methoden 
vorangetrieben. Die gezielte gentechnische Herstellung von Antigenen ist sicherer in der 
Verwendung und gezielter in der Aktivität. Dennoch sind diese meist partikulären Impfstoffe 
entscheidend in der Anwendbarkeit eingeschränkt – schlicht aufgrund der Tatsache, dass die 
Impfung mit Antigenen alleine nicht immer die notwendige Immunantwort auslöst. Aus 
diesem Grund wird auf so genannte Adjuvanzien zurückgegriffen, die das Immunsystem 
stimulieren ohne selbst einen antigenischen Effekt zu haben. Die Zahl der für humane 
Immunisierung zugelassenen Adjuvanzien (Alum, MF59 und Virosomen) ist gering.  Wobei 
betont werden muss, dass allein Alum weltweit zugelassen.  
IC31® ist ein neues Adjuvans, welches aus dem kationischen, antimikrobiellen Peptid NH2-
KLKLLLLLKLK-COOH (KLK) und dem  Nukleotid ODN1a (oligo-(dIdC)13) welches von 
TLR9 erkannt wird.  
Die vorliegende Arbeit legt zum ersten Mal den molekulare Mechanismus hinter der Funktion 
von IC31® offen. Wir zeigen, dass KLK mit unterschiedlichen Membranen interagiert und 
darin, ohne Poren zu generieren, interkaliert. Dabei sind eine Lipid-induzierte Änderungen 
der Konformation des Peptids von random-coil zu einem β-Faltblatt und von einem β-
Faltblatt zu α-Helix, sowie KLK induzierte ultrastrukturelle Veränderungen der Membranen 
zu beobachten.  
Wir demonstrieren des Weiteren, dass KLK mit ODN1a aggregiert. Aufgrund der Ladung des 
Peptids und seiner Fähigkeit mit Membranen zu interagieren, lagert sich der Komplex an der 
Oberfläche von Zellen an. Wir zeigen weiters, dass die Anwesenheit von KLK die 
endozytotische Aufnahme von ODN1a in dendritische Zellen erhöht. Wir haben das 
Nukleotid in frühen und späten Endosomen sowie im Endoplasmatischen Retikulum 
detektiert und darüber hinaus gezeigt, dass es mit TLR9 positiven Kompartimenten 
kolokalisiert. KLK sebst wird nicht in die Zellen aufgenommen sondern verbleibt vielmehr an 
der Plasmamembran.  
Durch die vorliegende Arbeit konnte zum ersten Mal die molekulare Wirkungsweise von 
IC31® dargestellt werden. Die Funktion der beiden Komponenten im Bezug auf die 
Stimulation des Immunsystems ist klar. Dadurch wird IC31®  zu einem der am Besten 
verstanden Adjuvanzien. 
Figure 1. Early vaccination critics
Early cartoon showing people with cows growing out of their bodies after being vaccinated with cow-
pox. The painting in the upper middle of the picture recalls the worship of the golden calf . (James
Gillray, 1802; Library of Congress, Prints & Photographs Division)
 2. Introduction 
 
Research is most interesting when multiple topics come together to create a new story and a 
conclusive picture about a particular subject.  In the course of this thesis our knowledge about 
the novel adjuvant IC31® gets more and more detailed, as the story starts from scratch with in 
silico studies of one component and leads to the observation of the fate of IC31® within the 
target cells. The examination touches diverse research fields that seemingly do not overlap at 
first, but are necessary to understand the function of IC31®.   
The introduction deals first with the history and problems of vaccination in general. At the 
end of this chapter a short outlook is given where the need for new adjuvants is emphasized. 
The already licensed adjuvants and some of the most promising substances are described in 
the next section before the two components of IC31® are detailed. Here, it is quoted that the 
mode of action of the adjuvant is dependent on the function of a cationic antimicrobial peptide 
and therefore describe general properties of these peptides in a detailed but important 
following chapter. Then key properties of dendritic cells, the target cells of IC31® are 
explained and finally, the introduction concentrates on the different cellular uptake routes that 
might be involved in the mode of action of the adjuvant.  
 
 
 
 
 
 
 
 
 
 
 2.1. Vaccination 
 
2.1.1. History 
 
Active immunization is one of the greatest success-stories in medical history. The eradication 
of smallpox and the worldwide reduction of polio are perhaps the best-known achievements 
of this medical intervention. Additionally, millions of lives were safed by routine vaccination 
against childhood-diseases such as measles or mumps and against tetanus. The theory of 
adapted immunity was essential for the development of this health intervention. In 430 B.C. 
Thukydides described the plaque of Athens. The inhabitants already recognized that people 
who survived the disease did not suffer from it again.  
The empirical roots of vaccination date back to ancient India and China were the technique of 
inoculation was discovered. People observed that smallpox appear in two distinct forms which 
were later identified as two different strains. The idea was to introduce a mild infection by 
blowing crusts of a pustule from a child with a less severe infection into the nostrils of an 
uninfected child.  At the early years of the 18th century Lady Wortley Montague learnt this 
technique in Constantinople and brought this knownledge back to London. Here, king Georg I 
could be persuaded after experiments with Newcastle prisoners and orphans to inoculate his 
grand daughters and later his grand son (for review see Grundy, 2000). In 1796, Edward 
Jenner, a surgeon in England, realized that people who were in contact with cows suffering 
from cowpox did not sicken from smallpox. So he started what we now call vaccination 
(vacca in Latin means cow) by inducing mild cowpox in humans that protected them against 
the disease. This approach turned out to be safer than inoculation which caused in a large 
percentage of treated people the severe form of smallpox (for review see Bazin, 2003).  
Very soon authorities realized that for the first time in history there was a tool at hand that 
could not treat but already prevent life threatening diseases and quickly introduced 
vaccination for whole population use.   
 
 
 
 
 
 
 2.1.2. Problems 
 
The major problems regarding vaccination today are not scientific restrictions – some will be 
mentioned at the end of this chapter – but the public opinion toward this medical technique. 
Interestingly, from the beginning of vaccination-history the emergence of vaccination critics 
and opponents can be observed. Not only because inoculation was unsafe, but for example 
because people feared the injection of material from cows as they expected to turn into cows 
themselves (Figure 1A). Vaccination is still a constant matter of debate. Every year 
discussions about the usefulness of the Influenza-vaccine fill the Austrian media. In the anglo-
american countries vaccination opponents claim a link between immunisation and autism. 
Most of these critics are marked by an enormous distrust of health autorities and 
pharmaceutical companies. Various scientific approaches were taken to examine the reasons 
for this opposition (Campbell et al., 2000; Sturm et al., 2005; Zimet et al., 2006; Marckmann, 
2008; Maurer, 2008).  
Especially, immunisation of children has to face an increasing opposition of laymen groups 
but also of people with scientific background endangering not only the health of their children 
– a fact that DDr. Wolfgang Maurer, a well known Austrian vaccinologist calls child-
maltreatment (Maurer, 2008) – but also a high number susceptible persons that can not be 
vaccinated as increasing numbers of unvaccinated people weakens the herd immunity (Fine, 
1993). As a matter of course, health authorities try to fight this negative development.  
Here, to keep the vaccination-levels high, some countries go for compulsory immunisations 
referring to ethics and fairness (May and Silverman, 2005; Asveld, 2008). Others reject their 
introduction as they would harm the “trust, choice and openness” of doctor-patient 
relationships (British Medical Association: Bord of Science and Education. 2003. Childhood 
Immunisation: A Guide for Healthcare Professionals). The problems caused by vaccination-
opposition seem to be increasing. The outbreak of measles in a school in Salzburg in the year 
2008 (Schmid D., 2008) is just the tip of the iceberg. In Germany the herd immunity 
regarding measles is decreasing and large outbreaks are reported regularly (Wichmann et al., 
2007; Muscat et al., 2009; Poethko-Müller et al., 2009). An easy solution is not in view, but a 
truthful publication even of problems in vaccine development and an explanation of motives 
behind the vaccination-strategies might form a mutual trust that allows to inform the 
population and the customers of the necessity and advantages of vaccination. 
 
 
 2.1.3. Outlook 
 
Although in the last century some deadly diseases could be eradicated or restrained by 
vaccination, others could not be fought. One explanation for the small number of available 
vaccines was the success of antibiotics that made many pathogens less threatening. Others 
were technological restrictions. Just lately it became possible to produce promising virus like 
particles, such as those used for HPV-vaccination. In addition, improved methods of DNA 
sequencing and protein prediction enable the design of new antigens and to test them for 
induction of immunity. In combination with novel vector systems, vaccination is not restricted 
anymore to communicable diseases. Every year millions of people dye from new epidemics 
like Alzheimer´s disease, obesity, high blood pressure or smoking (Zimmet and Alberti, 
2006). The call for “new imaginative strategies” of the WHO to fight these non 
communicable diseases might be answered by a “second vaccine revolution” (Dyer et al., 
2006). Here, the immunisation is directed against self-molecules like angiotensin II which is 
connected to hypertension. The new strategies face unique technical challenges as long-lived 
antibodies against self-molecules raise safety issues resulting from the potentially irreversible 
depletion of molecules targeted by vaccination. Further, the public opinion towards this 
progress might not be unproblematic. Comparable to the development of drugs against 
lifestyle diseases, vaccination against smoking or eating habits could endanger the mentioned 
trust needed for every immunisation-strategy.  
Due to new technologies, the future of vaccination is promising, but if we do not face the 
problems today we will reduce every possible success of the coming years. 
 
 
 
 
 
 
 
 2.2. A short overview of adjuvants 
 
2.2.1. Introduction 
 
The development of new generation subunit vaccines increases the safety of immunization. In 
1989, Janeway called adjuvants “the Immunologist´s dirty little secret”, as a great deal of 
ignorance existed that these subunit vaccines or killed whole organism require the addition of 
a helper (“adjuvare” in latin means “to help”) to be effective. Adjuvants stimulate the immune 
system and increase the response to a vaccine without having any antigenic effect itself. They 
are a heterogeneous group of compounds that can be composed of different constituents with 
different functions and activities, including carrier-, depot- or targeting functions (Guy, 2007). 
The current challenge facing adjuvant research is to find the “perfect mix” (Guy, 2007). It 
should be safe, the compounds should work synergistically and the adjuvant should drive the 
immune response into the desired direction and to the right cells. Generally, antigen 
presenting cells are the desired targets and here especially the dendritic cells (Gamvrellis et 
al., 2004). 
The first to work with adjuvant-like material was Dr. William B. Coley in 1891, who injected 
streptococcal organisms into a patient with a malignant bone sarcoma. The treatment 
stimulated the immune system of the patient and the tumor disappeared (for review see 
Espinoza-Delgado, 2002; McCarthy, 2006). The so called Coley´s toxins can be regarded as 
pathogen associated molecular patterns (PAMPs) which activate toll like receptors (see 
below). In vaccines, adjuvants are used since the early 1920s (for review see Cox and Coulter, 
1997). Glenny et al. tested the immunostimulatory properties of various precipitated 
diphtheria-toxoids. Among these were toxoids precipitated by addition of potassium alum 
(KAl(SO4)2 x 12H2O). These led to a significant increase in the immune response against 
toxins (Glenny et al., 1926).  The various forms of aluminium-based compounds became the 
first adjuvants for human application and are up to date the most widely used adjuvants.  
Until recently, the mode of action of alum was poorly understood. People suggested the depot 
formation and the related sustained release of the antigen as the major function of an antigen. 
In 2008 it was demonstrated that the NALP3 inflammosome is involved in the immuno-
stimulatory function of aluminium salts (see below) (Hornung et al., 2008; Núñez, 2008). 
Today, adjuvant candidates can be found rather easily. Every protein, toxin, peptide, salt, 
lipid, sugar etc. stimulating the immune system might be suitable. The restriction hampering 
 the application is the safety in humans. In the following section, the currently used adjuvants 
as well as the most promising approaches are described.   
 
2.2.2. Aluminium compounds 
 
Amoung the various aluminium salts, aluminium hydroxide and aluminium phosphate are 
most commonly used as adjuvants. The term alum restricted to potassium alum, KAl(SO4)2 
(for review see Lindblad, 2004). Precipitation of diphtheria toxin revealed the immuno-
stimulatory effects of Alum in 1926, and later of aluminium phosphate (Ericsson, 1946). In 
general, aluminium salts form a depot at the site of injection and are proposed to induce 
antibodies and TH2 responses via activation of the NALP3 inflammasome. The 
inflammosomes are multi-protein complexes in the cell cytoplasm. The complex is composed 
of an nucleotide domain leucine-rich repeat containing receptor (NLR), a cysteine protease 
caspase-1 and the adaptor molecule ASC that connects the NLR and the caspase (Agostini et 
al., 2004) and important parts of the innate immune system. Best studied is the NALP3 
inflammosome that is activated by multiple pathogen-associated molecular patterns (PAMPs) 
like degradation products of bacterial peptidoglycans. Recently, it has been demonstrated that 
crystalline structures like Amyloid-β, silica and asbestos and alum activate the NALP3 
inflammosome (Ennio De Gregorio, 2008; Hornung et al., 2008; Kool et al., 2008; Cassel et 
al., 2009). This leads to the cleavage of proIL-1β, IL-18 and IL-33 by caspase-1 into its active 
form and a subsequent inflammation due to the release of the active interleukins. The general 
ability of aluminium adjuvants to stimulate the production of IgE as part of the overall TH2 
profile is well-established (Hamaoka et al., 1973). This has been mentioned as a disadvantage. 
Anyhow, it has been difficult to demonstrate cases where vaccination with aluminium 
adjuvants has led to allergy towards the antigen (Lindblad, 2004).  
 
2.2.3. Emulsions 
 
One may discriminate between two prototypes of emulsions, water-in-oil inducing TH1 and 
oil-in-water inducing TH2 responses. The mechanism of action of adjuvant emulsions includes 
the formation of a depot at the injection site, allowing slow release of the antigen, and the 
stimulation of antigen specific B-cells (for review see Aguilar and Rodríguez, 2007).  
MF59, licensed by Novartis for a flu vaccine (Fluad®) in 1997, is an oil-in-water emulsion 
which induces like aluminium compounds a TH2 response (Podda and Del Giudice, 2003).  
 Montanide 720, is a water-in-oil emulsion (for review see Qiu et al., 2008) that has been used 
in trial vaccines agains HIV, malaria and breast cancer (Jones et al., 1990). The combination 
of Montanide 720 and CpG-DNA has recently been demonstrated to induce a mixed TH1/TH2 
response (Roohvand et al., 2007) which would be interesting for further applications.  
 
2.2.4. Saponins 
 
Saponins are steroid or triterpenoid glycosides found in wild or cultivated plants, lower 
marine animals and some bacteria (for review see Rajput et al., 2007). The triterpenoid 
saponins of the bark extract of the tree Quillaja saponaria was demonstrated to induce a TH1 
response and to increase immune cell proliferation in vitro (Chavali et al., 1987). But due to 
their toxicity they could not be use in human application. The development of semi-synthetic 
saponin derivatives that induce a TH1/TH2 response might open new possibilities for adjuvant 
applications (Marciani et al., 2003; Skene and Sutton, 2006). Anyhow, further studies are 
needed to prove efficacy and safety. 
 
2.2.5. Virus-like particles and virosomes  
 
Virus-like particles (VLPs) are based on viral capsid proteins which self-assembly into 
particulate structures closely resembling immature virus particles (Gheysen et al., 1989; 
Hagensee et al., 1993). The first step to virosome development was the generation of lipid 
vesicles containing viral spike proteins (Almeida et al., 1975). Today, virosomes are produced 
by detergent solubilization and reconstitution of enveloped viruses (Bron et al., 1993). All 
established VLPs proved to be strong stimulators of the innate immune system. The potential 
of VLPs to activate and mature DCs has been extensively investigated (Sailaja et al., 2007). 
Antigen specific stimulation of the immune system is achieved by expressing the antigens at 
the surface of VLPs (Huckriede et al., 2005).  
This method allows new approaches to the field of immunization as vaccines can now be 
directed against self-antigens. Various attempts using VLPs have already been made to 
prevent different non communicable diseases like obesity, smoking and high blood pressure 
with antigens against ghrelin, nicotine and angiotensin, respectively (Dyer et al., 2006). 
Further, VLPs can function directly as vaccines. Lately, they have been introduced in HPV-
vaccination (for review see Cutts et al., 2007) and might in the future play a role in 
immunization against HIV (Young et al., 2006 Buonaguro et al., 2006).  
 2.2.6. TLR-agonists 
 
Toll like receptors (TLRs) are critical for the innate immune response and will be described in 
more detail later. The various natural and synthetic TLR-agonists all exert immune-
stimulatory effects and are thus potentially applicable as adjuvants (for review see Pulendran 
Bali 2004; Lahiri et al., 2008). Different attempts are made to target TLR2 with OspA (Yoder 
et al., 2003), TLR4 with lipid A mimetics (Cluff et al., 2005), TLR5 with flagellin (Huleatt et 
al., 2007) and TLR3, TLR7, TLR8 and TLR9 with different nucleotides to induce an immune- 
stimulation. 
 
2.2.6.1. RNA and DNA 
One approach to stimulate the immune system is the in vivo-transfection of cells with RNA or 
DNA which would lead to an expression of the antigens encoded in the nucleotide sequence 
(Fynan et al., 1993). In this regard, the nucleotide would be used as vaccine. But the method 
is limited by a multitude of hurdles like their low transfection-potency in humans and the lack 
of suitable vector systems (Donnelly et al. 2003).  
In addition to the application of DNA and RNA as vaccines their potential role as adjuvants 
attracts a great deal of attention. TLR3, TLR7/8 and TLR9 recognize dsRNA, ssRNA and 
unmethylated CpG-DNA, respectively. Various synthetic substitutes of the nucleotides have 
also been implicated, like polyinosine-polycytidylic acid (poly(I:C)) for TLR3 activation 
(Matsumoto and Seya, 2008; Salaun et al., 2009), the imidazoquinoline compounds 
imiquimod and R-848 for TLR7/8 (Hemmi et al., 2002) and synthetic oligodeoxynucleotides 
containing unmethylated CpG motifs or poly(dIdC) for TLR9 stimulation.  
Due to stability reasons the phosphodiester-backbone of the nucleotides is often replaced by 
phosphorothioate. These modifications confer advantages like an enhanced binding of the 
DNA to the cell surface and protection from nuclease activity and are therefore thought 
suitable for clinical applications (Krieg et al., 1999). Unfortunately various side effects are 
published for the treatment with modified and unmodified CpG-DNA. In the murine system 
development of arthritis (Deng et al., 1999) and splenomegaly (Zhao et al., 1996) have been 
reported which would clearly limit the application in humans. 
 
The need for new adjuvants which are not restricted in regard to their application in humans is 
obvious. The availability of a broad spectrum of well understood adjuvants that stimulate the 
immune system in different ways allowing vaccine makers to choose the most suitable for 
 each vaccine would be beneficial. But though many immunostimulatory compounds are 
known, today only three adjuvans are licenced for humans in Europe (Alum, MF59 and 
virosomes in Fluad®) and only Alum is licensed in the United States. None of these is a good 
general inducer of a TH1 response which would be preferable for many diseases.  
 
2.2.7. IC31 
 
IC31®, developed and licensed by IntercellTM, represents a very promising adjuvant. At the 
beginning of the development IntercellTM experimented with DNA and RNA, as the immune-
stimulatory effect of these were already known. But the clinical application of nucleotides is 
limitated as, the material is quickly degraded administration of certain DNA can be harmful 
(Lipford et al., 1997; Sparwasser et al., 1997). Therefore, it was important to use an adequate 
nucleotide-sequence combined with a vector system for efficient delivery and stability. In this 
regard, cationic peptides have long been considered as useful tools to deliver DNA into cells 
and are still today interesting for gene-therapy (for review see Mann et al., 2008). 
Intercell demonstrated that a combination of CpG-DNA and the cationic peptide poly-L-
arginine, which is immuno-stimulatory itself, leads to a potent adjuvant with reduced side 
effects of the CpG-DNA (Buschle et al., 1997; Schmidt et al., 1997; Mattner et al., 2002). 
They considered that a combination of two immuno-stimulatory compounds represents a more 
potent adjuvant compared to one compound alone.  
After further experiments, the most promising combination, named IC31, was the nucleotide 
ODN1a (oligo-(dIdC)13), a single stranded DNA with a phosphodiester backbone and the 
short synthetic, cationic peptide KLK (NH2-KLKLLLLLKLK-COOH).  
Initially, KLK was found in a systematic screen for synthetic antimicrobial peptides (AMPs) 
of the active core of sapecin B from Sarcophaga peregringa (flesh fly) by Alvarez-Bravo et 
al. in 1994 and tested later for its antimicrobial activity (Nakajima et al., 1997). Initial 
experiments proved that KLK somehow interacts with membrane systems (Alvarez-Bravo et 
al., 1994) and exhibits immuno-stimulatory effects and induces a TH2-type immune response 
against co-injected antigens (Cho et al., 1999; Fritz et al., 2004). Interestingly, surface 
clareticulin was shown to be  involved KLK uptake and stimulation of neutrophils (Cho et al., 
1999). The signalling of ODN1a is dependent on TLR9 and induces an antigen-specific 
cellular type 1 response and a mixed type 1/2 humoral response. In any case, the presence of 
KLK was required for an immune response (Schellack et al., 2006). If IC31 is injected into 
mice, KLK is necessary to form a stable depot with a co-injected antigen at the site of 
 injection (Schellack et al., 2006). Interestingly, a control peptide of KLK with a proline 
substitution of the middle leucine named KPK (KLKLLPLLKLK) did not induce depot 
formation or immune-stimulation (Schellack et al., 2006). How the cationic antimicrobial 
peptide, KLK, contributes to the adjuvant activity, had to be demonstrated. 
 2.3. Antimicrobial peptides 
 
2.3.1. General properties of antimicrobial peptides 
 
All higher organisms need protection against bacteria, viruses and fungi. Beside the adaptive 
immune response, membrane active peptides and proteins play a crucial role in first line 
against microorganisms. Gene-encoded AMPs are conserved components of the innate 
immune response and widespread in nature, as they are synthesized by microorganisms and 
multicellular vegetal and animal organisms (for review see Bulet et al., 2004). The first AMPs 
were isolated by electrophoresis of a lysosomal fraction of guinea pig leukocytes (Zeya and 
Spitznagel, 1966) and named defensins. Many AMPs possess besides their antibacterial and 
antifungal activities, antiviral or anticanceral properties and can influence inflammation, 
proliferation, wound healing, release of cytokines, homeostasis and chemotaxis (for review 
see Kolls et al., 2008). AMPs are regarded as potential agents against antibiotic resistant 
pathogens (Zaiou, 2007). 
Today, more than 1000 antimicrobial peptides are known and collected in various data-bases 
(e.g. http://aps.unmc.edu/AP/main.php). To improve the effects of natural occurring peptides, 
a constantly increasing number of AMPs is generated synthetically that mimic sequences 
found in natural peptides (Isogai et al., 2008; Kitani et al., 2009; Yu et al., 2009). Although 
AMPs are chemically and structurally heterogeneous, all share three characteristics:  
 
1) They are small molecules with a molecular mass between 1 and 5 kDa.  
2) They are cationic or contain positively charged elements of 10-25 amino acids and 
 therefore often named cationic antimicrobial peptides (CAMPs). 
3) They have a tendency to form amphipathic structures in non-polar solvents.  
 
 
According to their size, molecular composition, conformational or predominant amino acid 
structure they are devided into groups that might differ from one publication to the other 
(Andreu and Rivas, 1998; Hof et al., 2001; Bulet et al., 2004). The following classification is 
representative and implies most of the characteristics (Hof et al., 2001): 
 
 
 1) linear peptides with an α-helical structure 
2) linear peptides with an extended structure characterised by overrepresentation of one or  
more amino acids  
3) peptides containing a looped structure  
4) conformationally more restrained peptides, predominantly consisting of β-strands 
connected by intramolecular disulfide bridges  
 
2.3.2. Interaction of AMPs with membranes 
 
Because of the above mentioned characteristics, AMPs have a strong affinity to phospholipids 
and it is generally assumed that their antimicrobial activity involves binding to the membrane 
bilayer of the target cell and thereby perturbing the membrane permeability or changing its 
ultrastructure. Upon their interaction with lipid membranes AMPs follow the same 
thermodynamic rules as other proteins and peptides (e.g. β-amyloid peptide (1-40)). Therefore 
interaction can be devided into three steps (for review see Seelig, 2004):  
First, an electrostatic attraction of the positively charged peptide to the negatively charged 
membrane occurs. Second, adsorption to the membrane structures and third, conformational 
changes and thus adoption of amphipathic structures can be observed (for review see Hof et 
al., 2001).  
A general feature is the conformational change upon interaction with the membrane. Many 
proteins and peptides like  the AMP melittin (Vogel, 1981) have a random coil conformation 
in solution and an α-helical structure when associated with a lipid membrane. The Alzheimer 
β-amyloid peptide (1-40) undergoes conformational transitions in the presence of negatively 
charged peptides. First from random-coil to β-sheet, and then, at a high lipid to peptide ratio 
into an α-helix. (Terzi et al., 1997).  
In general AMPs kill microbes by causing membrane leakage. Here, direct measurements of 
the peptide/membrane interaction are not possible and artificial liposomes are used to study 
the effects of AMPs. Thereby depending on the peptide (Bechinger, 1997) several models 
have been proposed to explain the molecular events taking place during the process that 
induce this leakage (for review see Oren and Shai, 1998; Bechinger, 1999; Shai, 1999; Hof et 
al., 2001).  
 
 
Figure 2.  Models of interaction of AMPs with phospholipid membranes
(A) Transmembrane helical bundle of mostly hydrophobic polypeptides. 
(B) Wormhole model. 
(C) Carpet model. 
(D) In-plane diffusion model.
(E) The disruption of the lipid bilayer packing due to in-plane inserted peptides is schematically 
illustrated for monomers and side-to-side dimers. (Bechinger, 1999)
 2.3.2.1. The barrel-stave model  
The barrel-stave model or helical bundle model is the classical picture where α-helical 
peptides insert into the membrane in a transbilayer orientation, and aggregate to form a pore 
(Mueller, 1975). The hydrophobic faces line the water filled lumen of the channel and the 
apolar residues point towards the membrane (Figure 2A). Even though this model was 
proposed 30 years ago, a conclusive demonstration of its validity was obtained only for 
alamethicin (Tieleman et al., 2002; Stella et al., 2007; Qian et al., 2008). The barrel-stave 
model has been questioned and as an alternative, the wormhole model was proposed.  
The wormhole model (Ludtke et al., 1996) is a modification of the barrel-stave model, where 
peptides form together with lipids the walls of the openings. Due to interaction of the peptide 
and the membrane, the lipid bilayer bends back and the outer and inner layer get in contact 
and form a pore (Figure 2B). This model was suggested for an antimicrobial peptide from 
Xenopus laevis, magainin (Ludtke et al., 1996). More recently, another mechanism, the 
“carpet” model was proposed. Therefore, the formation of wormholes possibly just reflects an 
intermediate state between the membrane micellisation and the peptide activity (for review 
see Bechinger, 1999).  
 
2.3.2.2. The carpet model  
The carpet model was first used to describe the mode of action of dermaseptin S (Pouny et al., 
1992). Later it was applied to various other AMPs like cecropins and LL-37 (for review see 
Shai, 1999). In this model, the membrane is fully covered by a carpet-like cluster of peptides 
(Figure 2C). Membrane permeation occurs, when a critical concentration of membrane-bound 
peptide is reached. In contrary to the barrel-stave model, the peptides are not inserted into the 
hydrophobic core of the membrane and the peptide does not need to adopt a specific structure 
upon its binding to the membrane. The AMP associates with the membrane surface, parallel 
to it, with the hydrophilic face oriented towards the water phase (Gazit et al., 1996). Finally, 
the membrane is disintegrated by the disruption of the bilayer curvature. On the molecular 
level the intercalation of peptides between the phospholipid head groups corresponds to 
insertion of a cone-shaped molecule into the membrane (Figure 2E). The formation of 
wormholes might be an intermediate state of the subsequent lysis process (for review see 
Shai, 1999; Hof et al., 2001).  
 
 
 
 2.3.2.3. Detergent-like effects 
Because peptides have earlier been observed to act as detergents (Schafmeister et al., 1993; 
Bechinger, 1997) the authors referred to it as detergent-like effect. The model is based on the 
intercalation of the peptides into the bilayer (Bechinger and Lohner, 2006). During the 
disruption of the membrane micellar structures can bud from the membrane of high local 
peptide concentration (Oren and Shai, 1998; Bechinger, 1999; Bechinger and Lohner, 2006).  
 
2.3.2.4 In-plane diffusion model  
In contrast to the carpet- and detergent-like model, the in-plane diffusion model applies to low 
peptide-to-lipid ratios (Figure 2E). The model is independent of cationic peptide aggregation. 
Insertion of a peptide into the lipid bilayer leads to a disturbance in the bilayer packing, 
leading to reduction of its thickness and finally to transient openenings (for review see 
Bechinger, 1999). 
 
Many artificial antimicrobial peptides used in clinical trials are derived from or mimic 
structures of natural antimicrobial peptides expressed in various organisms (see below). 
Natural, gene encoded AMP have limitations in the clinical application as they might act as 
signalling molecules of the immune system or cause other unintended effects. Thus, to 
generate the optimal active AMP, a large number of artificial peptides are designed and 
tested. 
 
2.3.3. Gen encoded and synthetic AMPs 
 
2.3.3.1. Gene encoded AMPs 
Gene encoded AMPs have been found in amoeboid protoczoa (Leippe, 1999), in prokaryotes 
(for review: Garneau et al., 2002; Nagao et al., 2006), in plants (for review see García-
Olmedo et al., 1998) and in many other organisms (for review see Andreu and Rivas, 1998; 
Bulet et al., 2004). The expression of the proteins and peptides can be constitutively as 
demonstrated for human β-defensin-1 (Krisanaprakornkit et al., 1998) or upregulated by acute 
infections like the the human LL-37 (Frohm et al., 1997). It has further been observed, that 
some peptides act specifically on different microorganisms. Insect defensins for example kill 
preferentially Gram-positive bacteria. As the steadily growing number of known AMPs would 
 go beyond the scope of this thesis, the following section turns the attention to a small 
selection of human antimicrobial peptides. 
 
2.3.3.1.1. Human antimicrobial proteins 
Here, three important groups of human antimicrobial peptides, the histatins, the defensins and 
the cathelecidin LL-37 will be discussed (for review see Smet and Contreras, 2005) while 
others like C-type lectins, S100 proteins or elastase inhibitors and their regulation (for review 
see Kolls et al., 2008) will not be mentioned.  
 
Histatins 
Histatins are a family of 24 small, cationic, histidine-rich peptides present in human saliva 
that have been reported to exhibit antibacterial and antifungal properties (Holbrook and 
Molan, 1973; MacKay et al., 1984; Pollock et al., 1984; Castagnola et al., 2004). These 
peptides are secreted from the submandibular, sublingual and parotid glands. As a part of the 
innate immune system they play an important role in maintaining oral health by limiting 
infections in the oral cavity. Histatin 5, which is formed by further processing histatin 3, has 
the strongest antimicrobial activity. As many other AMPs it shows a random coil structure in 
aqueous and an α-helix in non-aqueous solvents (Raj et al., 1998) but in contrast to other 
peptides, histatin 5 targets the mitochondria of fungi (Helmerhorst et al., 1999) or protozoa  
(Luque-Ortega et al., 2008) and not the cell membrane. 
 
Defensins  
Defensins are endogenous AMPs acting against bacteria, fungi, viruses and parasites. Ten 
human defensins have been identified yet that are differenciated according to their structure 
into α-defensins and β-defensins. Both groups are non-glycosylated, cystein-rich peptides 
with arginine as their primary cationic residue. α-defensins are smaller (29-35 amino acids) 
than the β-defensins (38-42 amino acids). Little primary sequence-homology between the two 
classes can be found but the tertiary structure is due to the presence of three disulfide bonds 
very similar. Defensins have a β-sheet structure (for review see White et al., 1995; Smet and 
Contreras, 2005) and can interact because of their amphiphilicity with membranes where they 
form ion-permeable channels (Lehrer et al., 1989, Kagan et al., 1990) to destroy the pathogen. 
Beside their antimicrobial activity, defenins have direct immuno-modulatory effects as they 
are for example able to influence the IL-1β secretion (Shi et al., 2007) or to activate  
monocyte-derived dendritic cells (Presicce et al., 2009).  
 The α-defensins can be found in B cells (HNP-1 to 3), natural killer cells (HNP-1 to 3) and in 
neutrophils (HNP-1 to 4), where they play a role in the oxygen-independent killing of 
phagocytosed micro-organisms. Two α-defensins (HD-5 and 6) are found in the Paneth cells 
of the smll intestine and in the epithelial cells of the female urogenital tract (Jones and Bevins, 
1992; Jones and Bevins, 1993). 
The β-defensins are expressed in various epithelia (hBD-1, hBD-2), in leukocytes and the 
bone marrow (hBD-2), keratinocytes (hBD-3) and human epididymis (hBD-4 to 6) (for 
review see Smet and Contreras, 2005). 
 
Cathelicidins 
The cathelicidin proteins are characterized by a highly conserved N-terminal domain – the 
cathelin-like domain. This is flanked at the N-terminus by a signal peptide and at the C-
terminus by the antimicrobial peptides. All cathelicidins are expressed and stored in cell 
granules and can be split on demand to produce release the AMP (Zanetti et al., 1995; for 
review see Dürr et al., 2006). While the uncleaved protein exhibits β-sheet conformations, the 
released AMP turns into an α-helical in membrane environments. Cathelicidins permeabilize 
the membranes (for review see Gennaro and Zanetti, 2000) and kill gram-positive and gram-
negative bacteria. Some cathelicidins like the human hCAP18/LL-37 have even toxic effects 
on eukaryotic cells and target also tumor cells. 
The 37 amino acid long LL-37 is the only cathelicidin found in humans. The short sequence 
represents the antimicrobial moiety of the precursor hCAP18. Beside the function as AMP, 
LL-37 has a role as signalling molecule and is thus found in a large variety of cells, tissues 
and body fluids (for review see Dürr et al., 2006). Further in mice it was demonstrated that 
human LL-37 binds and neutralizes LPS and therefore protects against an endotoxic shock 
(Larrick et al., 1995; Bals et al., 1999).  
 
2.3.3.2. Synthetic AMPs 
The significant effects of natural AMPs against micro-organisms are promising regarding 
clinical applications. However, some natural AMPs have to be administered in high doses, 
some act as signalling molecules and cause unintentional side effects. But the mature barrier 
to the use of AMPs as antibiotics is their toxicity or ability to lyse eukaryotic cells (Chen et 
al., 2005). Therefore, there are many attempts to design the optimal active AMP against 
bacteria (Scott et al., 2008), fungal infections (Ajesh and Sreejith, 2009), protozoan parasites 
 (Kitani et al., 2009) and additional infectious agends (Isogai et al., 2008; Kitani et al., 2009; 
Yu et al., 2009).  
Different approaches for the synthesis of a functional, artificial AMP exist (for review see Hof 
et al., 2001). Most promising is the design according to known natural antimicrobial peptides. 
Here, research in general concentrates on the peptide α-helices. These are regarded to confer 
the desired biocidal function. By truncation or mutation of the various regions, different 
synthetic peptides are designed and tested. KLK is an example of this approach. It was found 
in a systematic screen for synthetic AMPs of the active α-helical core of sapecin B from 
Sarcophaga peregringa (Alvarez-Bravo et al., 1994).  
A further method of AMP-design is the random synthesis of peptides and a combination of 
the designed peptides. The maximum applicable length of such peptides is 5 to 6 amino acids 
which strongly limits the possibilities of this approach. Both presented methods base on trial 
and error.  
But, as helicity, amphiphaticity, hydrophobicity and charge can be calculated, a rational 
design is possible (Frecer et al., 2004). The method is limited as the antimicrobial effects of a 
peptide are not easy to predict and structures are strongly interrelated. Therefore, the 
examination of peptide properties and the effects of AMP-mutation will lead to a broader 
understanding of the connections. This will allow advanced design of suitable antimicrobial 
peptides. 
 
 
 
 
 
 
 
 
 
 2.4. Dendritic cells 
 
2.4.1. Introduction 
 
Foreign antigens commonly invade the host through the skin or the epithelia of the 
gastrointestinal and respiratory system. Pathogens are therefore primarily captured in 
peripheral tissues that are distinct from the primary lymphoid organs (for review see Moser 
and Murphy, 2000). These pathogens and also injected vaccine-antigens are recognized by a 
group of immune cells that are key constituents of innate and later adapted immunity. 
Dendritic cells (DCs) represent the major class of antigen presenting cells (APCs) of the 
immune system (for review see Banchereau et al., 2000) and sentinel pathogens and antigens 
in peripheral tissues. DCs interact with T, B, natural killer (NK) and natural killer T (NKT)  
cells to guide the development of the immune response (for review see Creusot and 
Mitchison, 2004).  
Multiple subclasses of DCs with distinct life span, immune functions and surface markers 
have been identified (Shortman and Naik, 2007). The DC subtypes found in steady-state 
mouse and in human include type-1 interferon-producing plasmacytoid DCs (pDCs) and the 
nonlymphoid tissue migratory and lymphoid tissue-resident conventional DCs (cDCs) (for 
review see Wu and Liu, 2007; Merad and Manz, 2009). The monocyte-derived DCs (mDCs) 
are the best example for a DC-type produced not in steady-state but upon inflammation (for 
review see Shortman and Naik, 2007).  
The main function of pDCs is to secrete type 1 interferon in response to viral infections and to 
prime T cells against viral antigens (for review see Liu, 2005). The pDCs are derived from 
lymphoid progenitor cells and can be characterized by specific surface markers. Human pDC 
express CD4, CD45RA, high levels of CD123 and very low level of CD11c. The neuronal 
receptor, BDCA4, on the surface is often used to isolate pDCs. In contrast to cDCs they do 
not efficiently migrate to peripheral tissue.  
cDCs have two main functions: the maintenance of self-tolerance and the induction of specific 
immune responses against invading pathogens (for review see Banchereau and Steinman, 
1998). In general, myeloid precursors are the main source of cDCs (for review see Shortman 
and Naik, 2007). They can be divided according to their tissue localization (for review see Wu 
and Liu, 2007; Merad and Manz, 2009). The best studied subtype of cDCs are the skin 
resident Langerhans cells (LCs) that were already described in 1868 (Langerhans, 1868). 
 Epidermal LCs are derived from haematopoietic precursor cells but can renew locally. They 
express high levels of CD11c, CD1c, CD1a and can easily identified based on the expression 
of CD45. Typical for LCs is the expression of the lectin langerin that forms the 
intracytoplasmic birbeck granule (for review see Merad and Manz, 2009).  
The major function of mDCs is the immune response against invading pathogens. mDCs are 
developed during inflammation. There are two monocyte subsets that vary in chemokine 
receptor and adhesion molecule expression, in migratory and differentiation properties. 
“Classical” CD14+CD16+ monocytes in humans express CCR2, CD64 and CD62L. 
“Nonclassical” human CD14lowCD16+ monocytes lack CCR2 (for review see Wu and Liu, 
2007). Monocytes are recruited to the site of inflammation where they can react upon danger 
signals due to the expression of toll like receptors (TLRs). The subsequent signalling deflects 
the normal pathway of differentiation towards increase DC development (Nagai et al., 2006).  
Beside the differences of the subtypes, all DCs share common features. All take up antigens 
via different routes, the process the antigens and present them to T cells. These common 
features will be discussed in the following chapters. 
 
2.4.2. Dendritic cell surface, membrane and membrane turnover 
 
The diverse uptake routes of dendritic cells are well studied (Steinman et al., 1976; Steinman 
et al., 1983; Sallusto et al., 1995; Norbury, 2006), but interestingly, publications concerning 
specificities of the dendritic cell-membrane are scarce. The importance of the membrane 
composition is often underestimated as the lipid composition is in many regards a driving 
force of important functions like phagocytosis (Yeung and Grinstein, 2007) or the formation 
of the immunological synapse (IS). 
DCs interact with T cells by forming the IS - a specialized contact between membranes of two 
different cell types (Figure 3). Beside multiple receptors that are involved in the synapse-
formation, glycosphingolipid-enriched membrane microdomains play an important role in 
helping to form the structure of the IS (Janes et al., 1999; Ilangumaran et al., 2000; Burack et 
al., 2002). Such lipid rafts are also linked to various endocytic pathways (Hanzal-Bayer and 
Hancock, 2007). Recently, it has been shown that endocytosis of major histocompatibility 
complex (MHC) I and MHC II is dependent on different lipid rafts (Knorr et al., 2009). 
Therefore, examining the membrane composition of various cells may also lead to an 
advanced understanding of many AMP-functions.  
 Today it is well known that the surface of the dendritic cell exhibits negative charges due to 
for example negatively charged surface-proteins or anionic lipids containing 
phosphatidylserine (Henson et al., 2001; Foged et al., 2004) and attraction of positive material 
to the cell has been shown to potentiate its uptake into the cell. This might explain the 
significant uptake capacity of positively charged PLL-coated polystyrene particles compared 
to negative particles (Thiele et al., 2001). Further, preferred interaction of positively charged 
liposomes compared to the negatively charged counterparts (Foged et al., 2004) has been 
demonstrated. Specific interactions with positively charged peptides as suggested from in-
silico-experiments have also been studied in dendritic cells (Seelig, 2004). Recently, it has 
been shown, that removing of surface sialic acid of immature monocyte derived DCs 
decreases endocytic activity (Videira et al., 2008).  
It is obvious that the effect of the positively charged KLK is closely related to the surface of 
the target cells. Thus, it would be of importance to gain knowledge regarding the composition 
of the target DC membrane. Data on the lipid composition of dendritic cells are scarce. The 
most convincing data were published by Laulagnier and co-workers who described a molar 
percentage of total phospholipids, which was 43:23:12:9 Phosphatidylcholin (PC) / 
Phosphatidylethanolamine (PE) / Phospatidylserine-Phosphatidylinositol (PS-PI) / 
Sphingomyelin (SM) for dendritic cells (Laulagnier et al., 2004).   
The uptake of a membrane-bound substance is linked to membrane turnover (Betz et al., 
1996). This is generally regulated by the exocytosis-endocytosis cycle (Molecular Biology of 
the Cell; 4th edition; Alberts et al.; page 762). Therefore a dendritic cell with a high 
endocytosis rate (Sallusto et al., 1995; Steinman et al., 1999; Norbury, 2006) is supposed to 
have superior membrane turnover and a high uptake of membrane bound materials (Steinman 
et al., 1976; Steinman et al., 1983).   
 
2.4.3. From antigen uptake to presentation 
 
Immature DCs reside in peripheral tissues where they sense antigens or danger signals via 
various receptors (e.g. TLRs, mannose-receptor, etc.). External antigens are taken up via 
distinct mechanisms. Although, DCs are not involved in direct clearance of pathogens they 
express a large array of phagocytic receptors and effectively phagocyte pathogens (Ariel 
Savina, 2007). Large quantities of fluid-phase solute are taken up via macropinocytosis 
(Sallusto et al., 1995; Norbury, 2006). The majority of exogenous ligands bind to receptors at 
 the surface that are endocytosed via clathrin coated pits (Khan et al., 2007) and some via 
clathrin independent pathways (Steinman et al., 1999; Khan et al., 2007; Barral et al., 2008).  
As mentioned above, DCs can also recognize pathogen associated molecular patterns 
(PAMPs), such as unmethylated DNA, single stranded RNA, Lipopolysaccarides (LPS, 
(Iwasaki and Medzhitov, 2004) and damage associated molecular patterns (DAMPs), such as 
uric acid (M. A. M. Willart, 2009) via different receptors. Some of these danger signals also 
have to be taken up into the cell to interact with their receptors. Unmethylated CpG-DNA has 
for example been demonstrated to interact with TLR9 in distinct vesicles within DCs (Latz et 
al., 2004). These signals and patterns stimulate immature DCs and lead to expression of 
various cytokines but unlike antigens, they are not presented to T- or B-cells. 
Following exposure to the antigen or other stimuli, DCs undergo maturation that converts the 
primarily antigen sensing immature DCs to specialized antigen presenting cells and T-cell 
activators in the lymphoid organs. The maturation includes the presentation of an antigen via 
major histocompatibility complex (MHC), the migration of the dendritic cells to the lympoid 
organs, the reduction of endocytic activity and the change of expression patterns of various 
cytokines and chemokines (for review see Granucci et al., 1999).  
External antigens taken up by APCs are processed by proteases into peptides while travelling 
the endocytic route (Bryant et al., 2002). In late endosomal vesicles these peptides are 
acquired by newly synthesized MHC class II molecules (Bryant and Ploegh, 2004). Immature 
DCs are not capable to creat class II-peptide complexes. Here MHC II is stored in MHC II-
enriched compartments (MIICs). In these compartments the peptide binding groove of the 
MHC II molecule is occupied by a polypeptide, the CLIP fragment. Only upon stimulation of 
DCs for example by LPS, the CLIP fragment is replaced by an antigen (Alfonso and Karlsson, 
2000) and the loaded class II-peptide complexes are transported via tubular organelles to the 
plasma membrane (Kleijmeer et al., 2001).  
Cytoplasmic antigens like viral proteins but also external antigens that where exported into 
the cytosol (Savina and Amigorena, 2007) can be processed by proteasomes into eight to nine 
amino acid peptides. These are transported into the endoplasmic reticulum (ER) by the 
transporter associated with antigen processing (TAP, Wright et al., 2004), if necessary 
trimmed by the ER aminopeptidase associated with antigen processing (ERAAP, Serwold et 
al., 2002) and loaded onto MHC I molecules. The loaded MHC I molecule then travels via the 
Golgi apparatus to the cell membrane, exposed to the cell surface where it is accessible for 
CD8+ T cell (Peter Cresswell, 2005).  
 The turnover of dendritic cells in the tissue is very slow (t1/2 ~ 14-30 days in the skin, for 
review see Alvarez et al., 2008). During migration dendritic cells detach from the peripheral 
tissues and migrate to the local draining lymph node (LN) where they interact with homing T 
cells. Besides PAMPs and DAMPs, TNFα and IL-1β play a critical role as initial mobilization 
signals which seem also to be involved in detachment by reducing for example the E-cadherin 
expression of Langerhans-cells (LCs) in the skin (for review see Alvarez et al., 2008). The 
DCs pass the barriers of the extracellular matrix (ECM) and travel to the LN whereat 
chemokine (C-C motif) receptor 7 (CCR7) and its ligands, chemokine (C-C motif) ligand 19 
(CCL19) and CCL21, are the primary chemokines responsible for the migration. Stimulation 
with TNFα increases the expression of CCL21 by lymphatic endothelial cells and making 
them more attractive to migrating DCs (for review see Martin-Fontecha et al., 2003).  
In the lymph node antigen specific naïve T cells recognize via their T cell receptor (TCR) the 
antigen presented via the MHC. Depending on the MHC class the antigens are loaded at 
different types of T cells that are then activated. Peptides presented by the class I molecules 
are recognized by CD8+ cytolytic (or cytotoxic) T lymphocytes (CTLs) whereas CD4+ helper 
T cells interact with MHC II and are polarized towards Th1, Th2 responses or to Th17 cells 
(Infante-Duarte et al., 2000). The activation of antigen specific T cells is dependent on the 
formation of a prolonged but dynamic interaction named immunological synapse between the 
DC and the T cells (Figure 3). This specific synapse departs from the concentric bull´s eye 
pattern  for the T cell-B cell and T cell-planar bilayer interactions (Brossard et al., 2005). 
Leucocyte function associated antigen 1 (LFA-1) of the T cell and intercellular adhesion 
molecule 1 (ICAM-1) of the dendritic cell form narrow interactions whereat the distance of 
the resulting cleft is still under debate (for review see Brossard et al., 2005; Dustin et al., 
2006; Figure 3B). The formation of this tight apposition is essential for the activation of T 
cells but interestingly, it seems not to depend on the formation of one stable interaction of an 
antigen specific TCR with an antigen loaded MHC but the serial engagement and triggering 
of the TCR by peptide-MHC (for review see Lanzavecchia and Sallusto, 2001). Besides LFA-
1 and ICAM-1 that form the synapse, a set of co-stimulatory molecules like CD80 and CD86 
expressed by the dendritic and CD28 and CD2 expressed by the T cell cell is involved in the 
signalling and activation the latter.  
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Figure 3. The immunological synapse
A) Mechanisms that sustain and amplify signaling at the immunological synapse.
At the synapse, membrane molecules are organized in supramolecular clusters with short molecules, 
such as the TCR–CD3-ζ complex and CD28 (T cell), peptide-MHC and B-7 (APC), in a central region. 
Large molecules, such as LFA-1, and CD45, are found in the peripheral region. TCRs (in black) are
continuously internalized and recycled. Those that are engaged by peptide-MHC (red) are tethered into
raft microdomains containing PKC-theta, initiate the signaling cascade and are subsequently degraded. 
The number of rafts is developmentally regulated in naïve and primed T cells and can be increased by
costimulation. (Figure according to Lanzavecchia and Sallusto, 2001)
B) Immunological synapse patterns in T cell–DC interface and model systems.
(a) Fluorescence view of fixed T cell–DC immunological synapse (TCR is labeled green and protein
kinase C-θ is labeled red). A multifocal TCR cluster pattern is visualized. The TCR clusters each contain
in the order of 100 TCRs. (b) IS formed by T cells and supported planar bilayers that lack any diffusion
barriers (TCR is labeled green and ICAM-1 is labeled red). (c) IS formed on by a T cell on a patterned
planar bilayer in which chrome lines (dashed lines) disrupt diffusion of agonist MHCp and ICAM-1 in 
the bilayer (TCR is green and ICAM-1 is red). (Dustin et al., 2006)
 2.4.4. Stimulation of the Th1, Th2 and Th17 responses 
 
The existence of two different effector T-helper type (Th) populations, the Th1 and the Th2 
cells, was demonstrated more than 20 years ago (Mosmann et al., 1986). A third independent  
type, Th17, was described 14 years later (Infante-Duarte et al., 2000). The development of 
these different populations from naïve T cells is orchestrated by the costimulatory signals and 
the appropriate cytokine environment (Figure 4). These diverse populations are characterized 
by their differential cytokine production profiles and immune regulatory functions. The 
development of Th1 cells is potentiated by IL-12, which is released by APCs via a positive 
feedback loop. Th1 cells produce IFN-γ as well as IL-2 and lymphotoxin-β. The cells mediate 
defense against intracellular microbes and modulate isotype switching to immunoglobulin 
G2a (IgG2a) of B cells.  Mast cells, basophils and natural killer cells produce IL-4 that drives 
the development of Th2 cells. These cells produce IL-4, IL-5 and IL-13, mediate isotype 
switching to IgG1 and IgE and thus help clearing extracellular organisms like helminths. 
Further, via induction of IgE, Th2 cells play a role in allergic reactions (Kerri A. Mowen, 
2004; H. Bowen, 2008; Martinez et al., 2008). IL-6 and transforming growth factor-β induce 
the differenciation of Th17 (Bettelli et al., 2006) which produce IL-17, IL-17F, IL-21 and IL-
22. These cells indirectly induce the recruitment of neutrophils and macrophages to tissues  by 
regulating the secretion of granulopoietic factors (G-CSF and SCF), CXCL and CCL 
chemokines, matrix metalloproteases, pro-inflammatory cytokines and antimicrobial peptides, 
depending on the target cells (for review see Dong, 2008) and play a role in various diseases 
(for review see Martinez et al., 2008; Figure 4).  
 
2.4.5. Toll like receptors – TLR9 function and expression  
 
Toll like receptors (TLRs) are a family of conserved pattern recognition receptors (PRRs). 
TLRs are critical for the innate immune response as they recognize pathogen associated 
molecular patterns (PAMPS). TLRs are expressed in antigen presenting cells such as 
macrophages (Henning et al., 2008), dendritic cells, B-cells and monocytes (Kokkinopoulos et 
al., 2005), lymphatic endothelial cells (Kang et al., 2009), ovary and ovary-tumor cells (Zhou 
et al., 2009) and more.  
The expression profile of the different TLRs varies between distinct cell types (Figure 5) – as 
shown for the TLR9 below. Further, it has been demonstrated that TLR4-expression is lower 
Figure 4. Differentiation of T helper cell subsets
Naive CD4+ T cells, upon encountering their cognate antigens presented by professional antigen-
presenting cells (APC), differentiate into effector cells (TH1, TH2, TH17, iTreg) that are characterized
by their cytokine production profiles and immune regulatory functions. TH1 cells produce IFN-γ and 
regulate antigen presentation and immunity against intracellular pathogens, whereas TH2 cells, which
produce IL-4, IL-5, and IL-13, mediate humoral responses and immunity against parasites, and are
important mediators of allergic diseases. TH17 cells express IL-17, IL-17F, IL-21, and IL-22 (and IL-
26 in humans) and participate in inflammation and autoimmunity processes. iTregs express Foxp3 
transcription factor and mediate immune suppression by secretion of TGF-β and IL-10 and by contact-
dependent mechanisms. (Martinez, 2008)
 in older adults but that the cytokine production as a response to LPS stimulation is 
comparable to young adults (David van Duin, 2007). The first human toll like receptor was 
described in 1991 as the orthologe of Drosophila toll (Gay and Keith 1991) known today as 
TLR4. Up to the date, 13 mammalian toll like receptors have been identified, 10 in human and 
12 in mice (Beutler, 2004). Their extracellular domain contains 19-25 tandem copies of 
leucine rich repeat (LRR) motive (Galiana-Arnoux and Imler, 2006). The LRR domains of 
TLRs form a horseshoe structure, and it is thought that the concave surface of the LRR 
domains is involved directly in the recognition of various pathogens (for review see Akira and 
Takeda, 2004; Jin and Lee, 2008). TLRs have a conserved region of about 200 amino-acid 
that shows striking homologies to the IL-receptor and therefore named Toll/IL-1R (TIR) 
domain (Akira and Hemmi, 2003; Akira and Takeda, 2004). The binding of a ligand induces 
dimerization of the TIRs and a conformational change of these domains that is required for 
recruitment of downstream signalling molecules TLRs.  
The ligand specificity of the different TLRs is well studied. TLR1 and TLR6 interact with 
TLR2 at the plasma membrane to recognize bacterial lipid and mycoplasmal lipid, 
respectively, while TLR2 itself binds peptidoglycan, lipoteichoic acid and lipoproteins. The 
main ligand for TLR4 is bacterial lipopolysaccharide and for TLR5 it is flagellin (for review 
see Akira and Hemmi, 2003). All mentioned receptors are present at the membrane surface of 
the cells and recognize DAMPs in the environment. TLR3, TLR7, TLR8 and TLR9 on the 
other hand reside in the lysosomal compartments or are directed to this compartments as 
demonstrated for TLR9 (Latz et al., 2004). TLR3 recognizes double stranded RNA 
(Alexopoulou et al., 2001), TLR7 and TLR8 sense single-stranded RNA (Diebold et al., 2004; 
Heil et al., 2004), and TLR9 was primarily demonstrated to signal upon binding bacterial 
DNA (Hemmi et al., 2000) and synthetic oligonucleotides containing CpG-motives 
(Hartmann G., 2003).  
The recognition of DNA by TLR9 is not completely understood yet. It has been shown that 
several classes of small oligodeoxynucleotides (ODNs) bind to and stimulate TLR9 
transfected HEK cells in distinct dose-dependent relationships. B-class ODNs induce NFκB 
activation at lower doses than C- or A-class ODNs (Jörg Vollmer, 2004). Further, the 
different types of ODNs have been demonstrated to induce variable immune responses in vivo 
(for review see Marc S. Lamphier, 2006). Why these differences occur remains elusive. 
Recent data suggest, that it is not exclusively the bacterial CpG-sequence which is recognized, 
but that the detection of the DNA sugar backbone 2′ deoxyribose plays a pivotal role in the 
activation of the TLR9 (Wagner, 2008). The interaction between DNA and TLR9 occurs in 
 specific compartments. The group of Eike Latz has shown that TLR9 first resides in the 
endoplasmic reticulum and signals after translocating from the ER to tubular lysosomal 
compartments were it senses the CpG DNA (Latz et al., 2004). The localization of TLR9 
within this compartment plays a pivotal role in the prevention of self DNA recognition 
(Barton et al., 2006) and the cathepsin-cleavage of the receptor that seems to be critical for the 
subsequent signal transduction (Park et al., 2008) via MyD88.  
The expression of TLR9 in the various cell types is still a matter of debate. While the current 
dogma states that in humans this receptor is exclusively expressed in plasmacytoid dendritic 
cells (Iwasaki and Medzhitov, 2004; Wagner, 2004; Krieg, 2006; Figure 5) and not in 
Langerhans cells (Flacher et al., 2006) various other publications show that human monocyte 
derived and immature DCs also transcribe and express TLR9 (Kokkinopoulos et al., 2005; 
Hoene et al., 2006). Murine dendritic cells differ in this regard from their human counterparts 
and it is possible to obtain TLR9 positive cells by in vitro stimulation (for review see Iwasaki 
and Medzhitov, 2004).  
 
 
 
 
 
 
CD4+ CD8+ DN pDC GM-CSF+ IL4
TLR1 ++ ++ ++ ++
TLR2 ++ ++ ++ ++
TLR3 - ++ ++ -
TLR4 ++ ++/- ++/- ++/- ++
TLR5 ++ - ++ +
TLR6 ++ ++ ++ +
TLR7 ++ - ++ ++
TLR8 ++ ++ ++ ++
TLR9 ++ ++ ++ ++ ++
Freshly isolated DCs
In vitro
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Monocyte mDC pDC GM-CSF + IL4
TLR1 ++ ++ + ++
TLR2 ++ ++ - ++
TLR3 - ++ - ++
TLR4 ++ - - ++
TLR5 ++ + - +/-
TLR6 ++ ++ ++ ++
TLR7 +/- +/- ++ -
TLR8 ++ + - ++
TLR9 - - ++ -
TLR10 - + +
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In vitro
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B
Figure 5. Expression of Toll like receptors.
A) TLR expression of different human DC subsets and monocytes.  B) TLR expression of different 
murine DC subsets. +, ++ and – indicate relative mRNA expression levels of each TLR by the DC 
subsets. When both + and – are indicated, ambiguous expression patterns are published. (Iwasaki and 
Medzhitov, 2004)
 2.5. Endocytosis – coated and uncoated 
 
2.5.1. Introduction 
 
Cellular uptake mechanisms are essential for every cell. While the uptake of ions can be 
regulated by membrane transporters, in eukaryotic cells the uptake of receptor ligands, lipids, 
large particles or soluble molecules needs the formation of membrane-based pits and vesicles. 
The subsequent engulfment mechanism is called endocytosis. Endocytic systems are 
important for cells to get information about their immediate environment. Here, the different 
molecules and membrane proteins can be taken up by distinct and specific pathways. 
These pathways include phagocytosis, caveolae- and RhoA-mediated uptake, 
macropinocytosis and clathrin- and caveolin independent pathways (Figure 6). Best-studied is 
the clathrin mediated pathway, but clathrin-indipendent (CI) pathways are also in the focus of 
intensive research. An additional distinction between the uptake routes can be made by the 
involvement or absence of dynamin which mediates the fission mechanism.  
The mechanism of cargo selection for the different pathways is still a matter of debate. In 
clathrin-dependent endocytosis various adaptor molecules exist that recruit cargo to coated 
pits. One favours the involvement of micro-domains, another ubiquitination (Sigismund et al., 
2005) or lipid-based mechanisms (Mayor and Rao, 2004; Satyajit Mayor, 2004). If and how 
these different models interact stays elusive, but it becomes more and more obvious that all 
endocytic pathways except phagocytosis converge into transferrin receptor (TfR) positive 
early endosomes  (EEs) (for review see Mayor and Pagano, 2007; Figure 6). 
After the vesicle has formed and pinched off the plasma membrane in a dynamin-dependent 
or independent way, the fate of the intraluminal cargo is still not predetermined as recycling 
back to the plasma membrane can occur at various stages of the endocytic pathway (for 
review see Johannes and Goud, 1998).  
At the level of early endosomes, housekeeping receptors are uncoupled from their ligands at 
the pH ~ 6.2 milieu. The subsequent distribution is depending on the presence of different 
GTPases of the Rab-family. Domains containing Rab4 are thought to bud off and move to the 
plasma membrane. The Rab7 domains contribute to the biogenesis of late endosomes and 
transport of cargo to the lysosome (for review see Spang, 2009).  
Further, as counterbalance of membrane and protein transport to the plasma membrane, 
retrograde transport exists. Using partly endocytic pathways, cargo is transported back to the 
Figure 6. Cellular internalization pathways
Large particles are internalized by phagocytosis. The uptake of fluid occurs by macropinocytosis. Both
processes are dependent on actin-mediated remodelling of the plasma membrane. Additional major
internalization pathways include the clathrin- and caveolin-dependent endocytotic processes. The
vesicles formed by phagocytosis and macropinocytosis are considerably larger than the vesicles of the
other pathways. 
Numerous cargoes can be internalized via clathrin and dynamin indipendent pathways. Here, most
internalized cargoes are delivered to the early endosome via vesicular (clathrin- or caveolin-coated
vesicles) or tubular intermediates (known as clathrin- and dynamin independent carriers (CLICs)) that
are derived from the plasma membrane. (Mayor and Pagano, 2007)
 Golgi apparatus and to the endoplasmic reticulum. From the early endosome to the trans 
Golgi network (TGN) at least two independent retrograde routes have been observed (for 
review see Pavelka et al., 2008). One leads to the TGN via late endosomes (Barbero et al., 
2002) while the other one is a direct route from early and/or recycling endosomes to the TGN, 
thus bypassing late endosomes (Mallard et al., 1998).  
The presence of various proteins drives the selection for the retrograde transport of different 
cargoes within the early endosome. Transport of Shiga toxin from the EE to the TGN is 
dependent on epsinR (Mallard et al., 1998). Retrograde transport of the yeast S. cerevisiae 
carboxypeptidase Y receptors involves the vacuolar protein sorting (VPS)-subcomplex 
(Seaman et al., 1998). SNX1 (sorting nexin1), a homologue of the VPS5 protein has been 
found in mammals (Horazdovsky et al., 1997). In both pathways the involved proteins are 
supposed to polymerize on the endosome, deform the membrane into a tubular structure and 
allow a transfer of material to the TGN (Spang, 2009). 
 
2.5.2. Dynamin dependent pathways 
 
The large molecular weight GTPase, dynamin, has been linked to the late stages of endosomal 
vesicle-budding. The first hint for the function of dynamin came from the study using a 
temperature sensitive mutant of the gene shibire in Drosophila melanogaster (Kosaka and 
Ikeda, 1983). It was observed, that the formation of coated vesicles from coated pits was 
inhibited at high temperature. Morphological analysis revealed an accumulation of membrane 
invaginations and coated pits at the neuromuscular junction suggestive of a defect in the 
scission of coated pits to form coated vesicles (Kosaka and Ikeda, 1983). Later, dynamin has 
been identified as the mammalian homologue of shibire (van der Bliek and Meyerowrtz, 
1991). Dynamine participates in both the late stages of invagination and scission. It is 
recruited to the neck of a coated vesicle where GTP binding and hydrolysis by dynamine is 
required to form a deeple invaginated coated pit. During invagination and scission, dynamine 
might interact with binding partners like endophilin or amphiphysin (Hill et al., 2001).  
 
2.5.2.1. Clathrin mediated endocytosis 
Clathrin-mediated endocytosis is the major pathway for the uptake of nutrients and signalling 
molecules in higher eurkaryotic cells (for review see Ungewickell and Hinrichsen, 2007).  
Clathrin-coated pits (CCPs) have a diameter from 10 to more than 500 nm and were first 
characterized in oocytes of the mosquito Aedes aegypty by electron microscopy (Roth and 
 Porter, 1964). The formation of such coated pits starts with internalization signals located in 
the cytoplasmic tails of transmembrane proteins such as ubiquitin (Traub and Lukacs, 2007). 
These signals are recognized by the tetrameric adaptor protein AP-2 or monomeric adaptors 
like ARH, Dab2 and Eps15 (Rapoport et al., 1998; Matthew J. Hawryluk, 2006; Chaudhuri et 
al., 2007; Doray et al., 2007). All of these adaptor molecules except Eps15 can bind clathrin 
and contain phosphoinositide-binding modules that target them to the plasma membrane. 
Eps15 is important to recruit several proteins of the clathrin mediated pathway.  
Clathrin is recruited to these adaptor proteins and forms polyhedrical structures around the 
pits (Heuser, 1980). The invagination of the membrane was demonstrated to be clathrin-
dependent (Hinrichsen et al., 2006) but the presence of clathrin is not sufficient for membrane 
curvature to take place (Ralph Nossal, 2001). The nascent CCP is pulled back by myosin 
motor proteins that move alongside actin filaments (Girao et al., 2008; Idrissi et al., 2008) and 
scission involving dynamin releases the pit from the plasma membrane (Kosaka and Ikeda, 
1983; Hill et al., 2001). In addition it was shown, that invagination and scission are a highly 
dynamic and temporally coordinated process (Merrifield et al., 2005).  
 
2.5.2.2. Caveolin dependent endocytosis 
Caveolae are 50-80 nm flask shaped, non-coated plasma membrane invaginations present in 
many cell types, but mainly characteristic to endothelial cells (for review see Mineo and 
Anderson, 2001; Parton, 2003; Parton and Simons, 2007). These structures were first 
described in the early 60´s by electron microscopical analysis by George E. Palade and Eichi 
Yamada (Palade, 1953; Yamada, 1955). The caveolar membrane has shown to be enriched in 
cholesterol (Rothberg et al., 1990) Caveolae-mediated endocytosis is dynamin-dependent and 
associated with the turnover of lipid-rafts (for review see Simons and Ikonen, 1997) and 
glycosyl phosphatidylinositol-anchored proteins (GPI-APs; for review see Mayor and Pagano, 
2007).  
Various cargoes like cholera toxin B (Torgersen et al., 2001) are also known to be taken up 
not only by this pathway but also via a dynamine independent route. Further, cell type specific 
differences exist, as for example albumin is internalized in some cell types via caveolae 
(Schnitzer and Oh, 1994), whereas others use RhoA-dependent pathway (Cheng et al., 2006).  
The expression of caveolin 1 is sufficient to generate caveolae in cells that lack these 
structures initially (Lipardi et al., 1998) and caveolin knock out mice do not have obvious 
caveolae (Drab et al., 2001; Razani et al., 2002).  Therefore, it became a commonplace to 
equate caveolar functions with that of caveolin (for review see Nichols, 2003). Interestingly, a 
 subpopulation of caveolin-1-positive caveolae was identified which is not actively involved in 
budding and trafficking but static at the plasmamembrane. It is still a matter of debate, how 
the switch between the dynamic and the static caveolae is regulated (for review see Nichols, 
2003). 
Beside the already described early and the recycling endosome the existence of a so called 
caveosome is claimed. This would function as a transport intermediate between the caveolae 
and the endosomes. It has initially been studied during the vesicular transport of the simian 
virus 40 to the ER (Pelkmans et al., 2001) and has later been regarded important for the entry 
of human papillomavirus type 31 (Smith et al., 2008). Whether recycling back to the plasma 
membrane is possible at the level of the caveosome has to be demonstrated (for review see 
Spang, 2009).   
 
2.5.2.3. RhoA-dependent pathway 
As previously described, Eps15 is an important adaptor molecule for the formation of 
clathrin-coated pits. A dominant negative mutation of the protein-recognition domain of 
Eps15 leads to a selective and efficient blockage of both constitutive and ligand-induced 
clathrin dependent uptake. Using this system, IL2 has been demonstrated to be taken up via a 
dynamin dependent, Rho-GTPase regulated pathway that is distinct from the caveolae-
mediated uptake route (Lamaze et al., 2001). Although little is yet published, recent data 
suggest that RhoA-dependent uptake is involved in the trafficking of a voltage-sensitive 
potassium channel (Stirling et al., 2009) and has been implicated in the Oligophrenin1 mouse 
model of mental retardation (Khelfaoui et al., 2009). 
 
2.5.3. Dynamine independent pathways 
 
Expressing a temperature sensitive dynamin-mutant in HeLa-cells, Damke et al. demonstrated 
that the receptor mediated uptake of transferrin is inhibited, while the fluid-phase uptake 
recovers within 30 min to the wild-type level (Damke et al., 1995). They suggested an 
additional pathway that can compensate for the loss of clathrin- and caveolin-mediated 
endocytosis (Damke et al., 1995). The small GTPases CDC42 of the Rho family (Guha et al., 
2003) or ARF6 from the Arf family seem to be key proteins in the formation of these vesicles, 
whereas the exact role of the latter is not yet clear (for review see Mayor and Pagano, 2007).  
Inhibition of CDC42 was demonstrated to reduce the fluid-phase uptake of CHO cells and 
redistributing GPI-APs to the clathrin-mediated pathway (Sabharanjak et al., 2002). These 
 shifts concerning uptake of cargoe by alternative routes is well described. As mentioned, 
beside internalization via the caveolin-independent route, Cholera toxin B and GPI-anchored 
proteins (GPI-APs) have also been shown to be taken up into the cell via caveolin-dependent 
pathways.  
Thus it seems obvious, that a blocked uptake route can be replaced by the activity of another. 
The current theory suggests the dynamine-independent pathway as the main route for the non-
clathrin, non caveolar uptake of cholera toxin B (Torgersen et al., 2001), the plant protein 
ricin (Simpson et al., 1998, the Helicobacter pylori vacuolating toxin VacA (Gauthier et al., 
2005) and GPI-APs (Sabharanjak et al., 2002). There cargos can be detected in clatrhin- and 
dynamine-independent carriers (CLICs) (Kirkham et al., 2005) GPI-APs are directed into 
GPI-AP enriched early endosomal compartments (GEECs) which may form from CLICs 
(Sabharanjak et al., 2002). 
The specific uptake pathway for GPI-APs was first suggested after using GPI- and 
transmembrane-anchored isoforms of the same protein (Keller et al., 1992).  Today, GPI-APs 
represent the best studied cargo of the dynamin-independent pathway. Their association with 
detergent-resistant membranes (DRM) marks them as valuable markers for lipid-raft turnover 
(Sharma et al., 2002). It is important to note, that the location in DRMs does not implicate a 
specific uptake route, as for example the already mentioned IL2-receptor (Lamaze et al., 
2001) or anthrax toxin (Abrami et al., 2003), which are associated to DRMs but endocytosed 
via a RhoA- and clathrin-dependent pathways, respectively.  
 
 
 
 3. Materials and Methods 
 
3.1. Materials 
 
3.1.1. IC31 components 
 
KLKLLLLLKLK (KLK)   (10 mg/ml in water, IntercellAG) 
KLKLLLLLKLK-FITC (KLK-FITC) (10 mg/ml in water, IntercellAG) 
KLKLLPLLKLK (KPK)   (10 mg/ml in water, IntercellAG) 
ODN1a      (6705.1 µg/ml in water, Transgenomic, Inc.) 
ODN1a-Cy5      (1000 nmole/ml in water, Purimex) 
 
3.1.2. Dyes and Antibodies 
 
FM1-43, FM®
 
Lipophilic Styryl Dyes (Invitrogen) 
ER-TrackerTM
 
Green    (Invitrogen) 
DAPI       (Roche) 
Anti-human/mouse TLR9-FITC   (Eubio, Alexis) 
Anti-human CD71 (TfR)-FITC   (BD Pharmingen) 
Anti-human CD107a (Lamp-1)-PE   (BD Pharmingen) 
 
3.1.3. Media 
 
RPMI 1640      (PAA-Laboratories) 
DMEM-GlutaMAX    (PAA-Laboratories) 
L-Glutamine     (PAA-Laboratories) 
Sodium-pyruvate    (PAA-Laboratories) 
Non-essential amino acids   (PAA-Laboratories) 
Gentamycin     (PAA-Laboratories) 
 β-mercaptoethanol    (PAA-Laboratories) 
Fetal bovine serum (FBS)   (PAA-Laboratories) 
 Penicillin/Streptomycin    (PAA-Laboratories) 
IL-4       (Peprotech, Eubio; Cat.Nr.: 200-04) 
GM-CSF (human)    (Cell-Genix; Cat.Nr.: 1412-050) 
GM-CSF (mouse)    (X6310 cell supernatants; Reutterer et al., 2008) 
Yeast extract     (FormediumTM) 
Peptone     (BD Pharmingen) 
Dextrose     (AppliChem) 
 
 
YPD medium  
1% yeast extract, 2% peptone, 2% dextrose 
 
DC-medium (human) 
RPMI 1640,10% FBS, 1 % L-Glutamine, 1 % Sodium-Pyruvate, 0.1% β-mercaptoethanol, 1x 
Pen/Strep, 500 U/ml IL-4 and 0.1 μg/ml GM-CSF 
 
DC-medium (mouse) 
DMEM-GlutaMAX, 10% FBS, 1x Pen/Strep, 5% X6310 cell supernatant (Reutterer et al., 
2008).  
 
ECV-medium 
RPMI 1640, 10% FBS, 1x Pen/Strep 
 
HEK, C2C12, HELA, CaCO cell medium 
DMEM-GlutaMAX, 10% FBS, 1x Pen/Strep 
 
 
 
 
 
 
 
 
 
 3.2. Methods 
 
3.2.1. Studying membrane interactions of KLK 
 
3.2.1.1. Isolation of mitochondria  
DBY747 wild type cells (ATCC cat. No. 204659) and DBY747 mkh1Δ mutant cells (MKH1 
gene disrupted) (Froschauer et al., 2005) were grown overnight in YPD medium and 
harvested at stationary phase. Mitochondria were isolated as described elsewhere (Zinser and 
Daum, 1995) and resuspended in breaking buffer (250 mM Sucrose, 10 mM Tris-HCl pH 
7,4). Mitochondria were either processed immediately or stored at –80 0C until use.   
 
3.2.1.2. Preparation of yeast submitochondrial particles (SMPs) 
5 mg (about 0,5 ml in a typical yield) mitochondria were diluted to 1 ml in breaking buffer 
and further diluted 5-fold with low osmolarity buffer (10 mM Tris pH 7.4, 0.1 M sorbitol) and 
incubated on ice for 20 min in thick wall polycarbonate tubes (Beckman). The resulting 
mitoplasts were essentially without outer mitochondrial membrane as shown earlier 
(Nowikovsky et al., 2004). Particles were collected (40000 g´, 10 min at 4°C, Beckmann TL-
100 Ultracentrifuge), resuspended in 1 ml breaking buffer and tip-sonicated for 3 min at 80 % 
intensity on ice (Bandelin Sonoplus GM70 sonicator equipped with a UW 70 head, Berlin, 
Germany). Suspensions were pelleted (10000 g´, 10 min at 4°C), supernatants transferred into 
new tubes and SMPs collected by centrifugation (100000 g´, 1h at 4°C). Pellets were 
resuspended in 250 mM Sucrose buffer and stored at –80 0C until use. 
 
3.2.1.3. Loading SMPs with ion-sensitive fluorescent dyes 
SMP pellets (1 mg total protein) were resuspended in 1 ml sucrose buffer and 75 µM 
tetraammonium salt of the K+-sensitive fluorescent dye, benzofuran isopthalate, PBFI 
(Molecular Probes, The Netherlands), was added. Reactions were tip-sonicated on ice as 
described above to entrap the ion-sensitive fluorescent dyes within SMPs. Particles were 
collected by ultracentrifugation (100000 g´, 10 min), washed in buffer and resuspended in the 
same buffer at 0.05 mg protein per ml.   
 
 3.2.1.4. Fluorescence measurements 
Excitation wavelengths were set at 340 and 380 nm for PBFI, while the emission wavelength 
was set to 500 nm. Fluorescence emitted by both free and ion-bound dyes was recorded with a 
Perkin-Elmer LS-55 spectrofluorometer with Fast Filter Accessory mode. Measurements were 
performed in quartz cuvettes with a total volume of 2 ml while slow stirring at 25 0C. KLK or 
KPK and KCl, were added directly to the cuvettes at the indicated time points.  
 
3.2.1.5. Generation and loading with PBFI of large unilamellar asolectin 
vesicles 
100 mg of soybean asolectin phospholipids (Sigma-Aldrich, USA) were emulgeated in 1ml of 
ddH2O by sonication. The suspension was diluted 9-fold with HEPES-NaOH, 100 mM NaCl 
and 1 % CHAPS, pH 7.4 (Sigma-Aldrich, USA). Vesicles were formed by removing CHAPS 
by extensive dialysis against the above buffer without CHAPS for 48 h at 4 0C and collected 
by centrifugation at 100 000 x g for 30 min at 4 0C. Vesicles were washed once in CHAPS-
free buffer and vesicle pellet resuspended again in 200 µl of CHAPS-free buffer. Asolectin 
liposomes were loaded with PBFI as described for SMPs.    
 
3.2.1.6. Blood samples and osmotic resistance tests  
Heparinized human blood samples (100 IU/ml) were drawn from young healthy volunteers. 
Samples were centrifuged at 4000 g´ at room temperature for 10 min, the plasma and buffy 
coat were carefully removed, and the erythrocyte pellet re-suspended in physiological saline 
at 50% hematocrit. Samples (20 µl) of erythrocyte suspension were added to 8 ml of various 
osmolarity NaCl solution (50-300 mosmol in 25 mosmol increments). Samples were 
incubated at room temperature for 30 min, and centrifuged at 5000 g´ for 5 min. The 540 nm 
absorption of the supernatant was measured with a Perkin-Elmer Lambda 2 (USA) 
spectrophotometer. Complete hemolysis of the samples was induced by the addition of 0.1% 
Triton X-100 detergent, and the 540 nm absorption measured again. 
 
3.2.1.7. Erythrocyte ghost preparation and fluorescence emission 
anisotropy measurements 
Erythrocyte ghosts were prepared as described elsewhere (Dodge et al., 1962). Isolated ghosts 
were labeled with DPH or TMA-DPH as previously described (Miseta et al., 1995). 
Measurements were carried out with a Hitachi F-4500 fluorescence spectrophotometer 
 (Japan), equipped with polarization accessories, at 25 °C using wavelengths of 360 nm and 
425 nm for excitation and detection, respectively. Fluorescence anisotropy was calculated 
according to the equation r=(Ivv-GIvh)/(Ivv+2GIvh), where Ivv and Ivh are the fluorescence 
intensities measured with a vertical polarizer, and a vertically or horizontally mounted 
analyzer, respectively (G=Ihv/Ihh) (Donner and Stoltz, 1985). For each sample the fluorescence 
was corrected for the scattering effect of unlabeled ghosts.  
 
3.2.1.8. Preparation of small unilamellar vesicles and circular dichroism 
measurements 
Small unilamellar vesicles (SUVs) were prepared using 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC) and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG) 
lipid components (Sigma-Aldrich, USA). POPC and/or POPG at a molar ratio of 3:1 were 
diluted in chloroform and vacuum-dried. SUVs of 100 nm diameter were generated by 
extruding the water-reconstituted lipids through the membrane of the device Avestin-Extruder 
(LiposoFast). Circular dichroism measurements were performed on aqueous or NaP-buffered 
(20mM) of the peptides KLK and KPK in the absence or presence of POPC/POPG-SUVs 
using 10 mm path length quartz cuvette in a PiStar-180 CD spectrometer (Applied 
Photophysics). 20-80% 2,2,2-trifluoroethanol (TFE, Sigma-Aldrich, USA) were administered 
to KLK or KPK in water or phosphate buffer where indicated. 
 
3.2.1.9. Electron microscopy  
 
3.2.1.9.1. SMPs 
Submitochondrial particles (2 x 500 µl aliquots/sample) were placed on ice and treated with 
10 nmole/ml of KPK or KLK for 30 min. To the control sample, equal volume of sucrose 
buffer was added. SMPs were pelleted by centrifugation (40000 g´, 10 min at 4°C). Pellets of 
SMPs attached to the bottom of Eppendorf tubes were washed in Sorensen`s buffer (Hayat, 
1989). Subsequently, they were fixed with 3% glutaraldehyde in 0.15 M Sorensen`s buffer, 
pH 7.4, for 30 min.  The pellets were detached by using a small spatula and glutaraldehyde 
fixation continued for further 30 min. After washing, the pellets were postfixed with 1% OsO4 
in Sorensen´s for 1 h and dehydrated with increasing concentrations of ethanol. Finally, 
samples were embedded in epoxy resin Agar 100 (Agar Scientific Ltd, UK). Thin section of 
60-80 nm were cut with LEICA Ultracut S ultramicrotome, mounted on copper grids, 
contrasted by uranyl acetate and lead citrate, and examined at 80 kV in a JEOL JEM-1210 
 electron microscope (Jeol Ltd., Japan). Images were acquired using a Morada digital camera 
for the wide-angle port of the TEM and analySIS FIVE software (Soft Image System). 
 
3.2.1.9.2. Cell culture 
Human monocyte derived dendritic cells were treated with 100 nmole/ml KLK or KPK 
diluted in fresh medium. To the control sample an equal volume of fresh medium was 
administered. After 15 minutes the cells were pelleted by centrifugation (300 g´, 10 min at 
room temperature) and fixed with 3% glutaraldehyde n 0.15 M Sorensen´s buffer. Samples 
were subjected to postfixation and sectioning as described for SMPs. 
ECV endothelial cells were grown on ACLA-slides to a cell density of 80%. 100nmole/ml 
KLK in fresh medium was administered. To the control sample an equal volume of medium 
was added. After 5 minutes cells were fixed in 0.5 % glutaraldehyde using an EMS 
microwave (15 seconds and 50 % power). Postfixation was performed in 3 % glutaraldehyde 
for 30 minutes. Samples were processed as described elsewhere (Reipert et al., 2008). 
 
3.2.2. KLK distribution in SMPs 
 
3.2.2.1. MALDI-TOF mass spectrometry analysis of vesicular sub-fractions  
SMPs were ultracentrifuged and supernatants were saved (supernatant 1). Pellets were washed 
extensively, resuspended in reaction buffer and tip-sonicated to disrupt vesicles. Sonicated 
SMPs were again ultracentrifuged and supernatants (supernatant 2) and pellets (pellet) were 
separated. Samples were acidified by the addition of 1% trifluoroacetic acid (TFA)/water 
(20% v/v final) and extracted with diethylether to remove lipids. The samples were then 
purified via Ziptips C18 (Millipore, USA) for matrix assisted laser desorption/ionisation – 
time of flight (MALDI TOF) mass spectrometry analysis. Ziptips were wetted by aspirating 
and dispensing (cycling) pure acetonitrile and then equilibrated by cycling 0,1% TFA/water 
several times. Peptides were bound to Ziptips by cycling the sample solution through the tips 
several times. The tips were then washed by cycling 0,1% TFA/water through the tip. The 
purified peptides were eluted directly onto the target plate by aspirating approximately 2 µl of 
matrix solution [10 mg/ml alpha-cyanohydroxycinnamic acid (CHCA) in 
TFA/water/acetonitrile (0,1:50:50; v/v/v)] into the tip and cycling the solution a few times 
onto the target plate. Samples were analyzed on a Voyager DE-STR (Applied Biosystems, 
Darmstadt, Germany) in the positive ion reflection mode. External calibration was performed 
with the known masses of a synthetic peptide mixture. 
 3.2.2.2. Distribution of KLK-FITC within SMPs 
10 nmole/ml FITC-labelled KLK was administered to SMPs. These were ultracentrifuged and 
supernatants were saved (supernatant 1). Pellets were washed extensively, resuspended in 
reaction buffer and tip-sonicated to disrupt vesicles. Sonicated SMPs were again 
ultracentrifuged and supernatants (supernatant 2) and pellets (pellet) were separated. Samples 
were analysed using a Zeiss Axioplan 2 Fluorescent microscope. 
 
3.2.3. Aggregate formation 
 
3.2.3.1. Gel retardation and particle size 
10 µg ODN1a was mixed with 40 µg KLK or KPK and loaded on a 2% agarose gel. Binding 
of KLK to the nucleotide was analyzed via gel-retardation of ODN1a. 
For the measurement of particle size distribution 0.4 nmole/ml ODN1a were mixed with 10 
nmole/ml KLK/KPK in water. 1ml of the mixture was analyzed using a Malvern Mastersizer 
2000. 
 
3.2.4. Cell culture experiments 
 
3.2.4.1. Preparation of human immature dendritic cells  
Whole human heparinized blood was obtained from the Red Cross and 500 ml of blood was 
diluted 1:1 in PBS. Diluted blood was placed on LSM 1077 lymphocyte separation medium 
(PAA, Austria) gradient and centrifuged for 20 minutes at 350 g. Monocytes were harvested 
and CD14
+ 
cells were selected by MACS purification (MiltenyiBiotech) and incubated in DC-
medium (human) at 37 °C in 5% CO2 for 7 days. At day 6 of culture, CD83 (below 10%), 
CD1a (50-70%) and MHCII (70-90%) were assured by FACS analysis. At day 7 non-adherent 
cells were collected and used in subsequent experiments.  
 
3.2.4.2. Preparation of mouse bone marrow derived dendritic cells and 
macrophages 
C57Bl/6 were housed under pathogen free condition according to FELASA guidelines 
(Nicklas et al., 2002) Bone marrow-derived DCs and macrophages were isolated and 
maintained according to (Reutterer et al., 2008). 
 
 3.2.4.3. Cultivation of HEK, C2C12, HELA and CaCo-cells 
Cells were cultivated in appropriate medium. At 80% density cells were splitted using 1x 
Trypsin for 5 minutes at 37°C. The cells were diluted to reach a density of 80% after 
incubation for 24 hours at 37°C in 5% CO2 and placed in an 8 well Lab-Tek II Chamber Slide 
(LAB-TEK®, Nunc).  
 
3.2.4.4. ODN1a-Cy5 uptake experiments 
Cells were placed in an 8 well Lab-Tek II Chamber Slide (LAB-TEK®, Nunc) at a density of 
1.5-3 x 105 cells per well and incubated over night at 37°C in 5% CO2 in appropriate medium. 
Fresh medium was added to the wells with ODN1a-Cy5 and KLK/KPK added to a final 
concentration of 0.4 nmole/ml (low dose) or 1.2 nmole/ml (high dose) and 10 nmole/ml, 
respectively. Where indicated 6 nM FM1-43 or 1 μM ER-tracker was added to the mixture. 
Cells were incubated for various lengths of time, washed once with PBS and then fixed for 30 
minutes at 37°C with 4% PFA (Sigma-Aldrich). Cells were washed twice with 0.5% Tween in 
PBS for 1 minute, rinsed once with PBS and then incubated with 2% BSA (Sigma-Aldrich) or 
2% goat serum (Vector Laboratories). In case of subsequent DAPI or antibody staining cells 
were exposed to 2µg DAPI diluted in 200µl PBS or anti-human CD71-FITC and anti-human 
CD107a-FITC diluted 1:33 in 2% BSA, or to anti-human/mouse TLR9-FITC dilutet 1:100 in 
2% goat serum for 1 hour at 37°C in a humid chamber. Cells were then washed two times 
with 2% BSA or 2% goat serum and once with PBS and examined using Zeiss Axioplan 2 
LSM510 Meta laser scanning fluorescence microscope. Images were subsequently analyzed 
using the Zeiss LSM ImageBrowser software.  
 
3.2.4.5. Localization of KLK experiments 
Cells were placed in an 8 well Lab-Tek II Chamber Slide (LAB-TEK®, Nunc) at a density of 
1.5-3 x 105 cells per well and incubated over night at 37°C in 5% CO2 in appropriate medium. 
10 nmole/ml FITC-labelled KLK in fresh medium was added. Cells were incubated for 1 
hour, washed once with PBS and then fixed with PFA as described before.  
 
3.2.4.6. Live cell laser confocal imaging 
At day 7 dendritic cells were collected and transferred to new dishes containing sterile glass 
cover-slides. Cells were incubated at 37°C in 5% CO2 over night. ODN1a-Cy5, KLK/KPK 
and dyes were mixed as described above. The medium was removed carefully from the cover-
slide and a few micro-liters of the mixture were placed on the slide. The glass slide was put on 
 an object slide and sealed before the sample was observed using a Zeiss Axioplan 2 laser 
scanning fluorescence microscope equipped with a LSM510 Meta camera. Images were 
processed using the Laser Scanning Microscope Version 3.2 SP program.  
 
3.2.4.7. FRET measurements 
FRET experiments were performed using FRET-pair forming fluorochrome-labeled components; 
KLK-TAMRA and ODN1a-Cy5. FRET efficiency was calculated with the acceptor-bleaching 
technique (acceptor: Cy5; Donor: Tamra) according to the formula FRETeff= (Intensitypost-
Intensitypre)/Intensitypost
 
with photo-bleaching corrections. For fluorescent imaging in FRET 
experiments, a modified epi-fluorescence microscope was used (Axiovert 200, Zeiss, Germany), 
which was equipped with a temperature control system (POCmini, Zeiss, Germany). Samples 
were illuminated through a 100x NA=1.45 Plan-Apochromat objective (Zeiss) using the 514 nm 
line (excitation of TAMRA) of an Ar+-ion laser (Innova, Coherent, USA) and 647 nm (excitation 
of Cy5) of a Kr+-ion laser at excitation intensities of up to 10kW/cm2 by using epi-configuration. 
An acousto-optic modulator (Isomet, 1205C) was used to achieve exact timing of the laser 
illumination. After filtering (custom-made dichroic and emission filters, Chroma, USA), images 
were recorded on a back-illuminated liquid nitrogen cooled CCD camera (Micro Max 1300-PB, 
Roper Scientific). Each CCD pixel corresponds to 200 nm x 200 nm in the sample plane. All live 
cell experiments were performed in Hank`s balanced salt solution (HBSS; PAA) at 37 °C. 
 
 
 
 
 
 
 
 
 4. Results 
 
4.1. Molecular properties of KLK 
 
The cationic antimicrobial peptide KLK (KLKLLLLLKLK) was originally found in a 
systematic screen of synthetic AMPs (Alvarez-Bravo et al., 1994) and tested later for its 
antimicrobial activity (Nakajima et al., 1997). KLK itself induces a predominantly TH2 
immune responses against co-injected antigens in vivo by stimulating the expression of high 
levels of antigen-specific antibodies against the model antigen ovalbumin (OVA) or a 
commercial influenza vaccine (Fritz et al., 2004).  KLK was efficient in enhancing association 
of antigen to antigen-presenting cells (APCs, including dendritic cells). IntercellTM combined 
KLK with the TLR9 agonist ODN1a. This two-component adjuvant was termed IC31®. Co-
injection of IC31® with appropriate immunogenic peptides or proteins induces a potent 
antigen-specific, predominantly type 1 T cell response and elicits antigen-specific cytotoxic T 
cell activity (Schellack et al., 2006). The protein-based vaccines are further capable of 
inducing antigen-specific mixed type 1 and type 2 humoral responses. It has also been 
demonstrated that IC31® efficiently stimulated the maturation and activation of dendritic cells 
(DCs) that in turn enabled the induction and proliferation of naïve T cells (Schellack et al., 
2006). 
Interestingly, a substitution of the middle leucine to proline results in a peptide with complete 
loss of its immuno-stimulatory properties. This peptide, KPK (KLKLLPLLKLK) exhibits the 
same amount of charged residues as KLK but behaves differently. While KLK forms a stable 
depot at the injection site, KPK does not (Intercell personal communication). Therefore, the 
first attempt to clarify the mode of action of IC31® was to examine the properties of KLK. 
Thus far, no studies had been published that aimed to resolve the structure of KLK and KPK. 
Such information would provide deeper understanding of biological functions of these 
peptides. 
 
 
 
 
 
 
 4.1.1. Conformational properties of KLK 
 
Our first experiments were performed using circular dichroism (CD) measurements. CD 
analysis allows a fast determination of the secondary structure of a given protein or peptide. 
The conformational properties of the protein or peptide can be monitored under various buffer 
conditions, in different pH, in presence of various ions but also in membrane mimicking 
environments like detergents or small unilammelar vesicles (SUVs). 
 
4.1.1.1. KLK undergoes various conformational transitions in presence of 
SUVs 
In water both KLK and KPK showed a typical random coil conformation (Figure 7A). To 
mimic a membranous environment, we added small unilammelar vesicles (SUVs) to the 
peptides. The SUVs contained the uncharged 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (POPC), the positively charged 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoglycerol (POPG) or a 3:1 molar mixture of POPC and POPG.  Addition of this 
mixture or of the uncharged POPC alone led to a prompt random coil to beta sheet 
conformational transition of KLK (Figure 7B).  
Because of the size of the peptide we consider this β-sheet structure as an intermolecular 
aggregation. The same amount of lipids administered to the control peptide KPK did not lead 
to conformational transitions even at higher lipid to peptide ratios.  
Positively charged proteins are attracted by negatively charged membranes, the proteins get in 
contact with the membrane and a conformational transition into an alpha helix can be 
observed (Seelig, 2004). Thus, in the following experiment increasing amounts of the 
negative charged POPG were administered to KLK and the conformational transitions were 
monitored. As demonstrated before, KLK exhibited random coil conformation in water. 
Addition of POPG led to a beta-sheet conformation. With increasing lipid to peptide ratios 
KLK showed a further transition from intermolecular beta-sheet to alpha helix (Figure 7C).  
Comparable to other peptides (Seelig, 2004) KLK is also capable of responding to the lipid 
environment with conformational transitions at the vicinity of membranes. These transitions 
could not be demonstrated for KPK. 
 
 
 
 
Figure 7. Conformation of KLK and KPK in presence of lipids
(A) Both KLK (black line) and KPK (dotted line) show typical random coil conformation in dH2O. (B) 
Conformational transition into β-sheet of KLK (black line) but not KPK (doted line) in the presence of 
POPG:POPC (1:3 molar ratio) SUVs at a lipid-to-peptite ratio of about 30. (C) Conformational 
transition of KLK at increasing lipid to peptide ratios. KLK exhibits random coil conformation in water 
(grey line). POPG triggers conformational transitions into β-sheet at low lipid to peptide ratio (15:1 
molar ratio; black dashed line) and α-helix at high lipid to peptide ratio (125:1 molar ratio; black line).  
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 4.1.1.2. Beta-sheet and alpha-helical propensity of KLK and KPK 
To further examine the conformational propensities of KLK and KPK, sodium dodecyl 
sulphate (SDS) and 2,2,2-trifluoroethanol (TFE) were included in the CD measurements.  
SDS was added to a buffer to create a hydrophobic environment that mimics membrane 
hydrophobicity (Moraes et al., 2007). As seen in Figure 8A, addition of 1% SDS led to a 
transition of KLK from random coil to beta-sheeted conformation. As demonstrated with 
uncharged SUVs, KLK readily formed a beta-sheet that was not dependent on available 
charges but seems to be induced by the hydrophobic environment. It can be argued that, in 
this situation, intermolecular interactions covering the positively charged lysines are 
energetically preferable. The presence of SDS did not affect the random-coil conformation of 
KPK (Figure 8A). 
2,2,2-trifluoroethanol (TFE) stabilizes alpha helical structures in proteins and peptides 
(Goodman et al., 1969) and can be used to determine the alpha-helical propensity of proteins 
(Segawa et al., 1991; Henrik et al., 1997).  
20% TFE was added to KLK in water. This prompted the formation of a clear alpha-helix 
(Figure 8B). The same amount of TFE administered to KPK did not change the conformation 
of this peptide (Figure 8B).  
 
4.1.1.3. Phosphate buffer stabilizes the beta-sheet conformation of KLK 
In a subsequent experiment we changed the buffer system and used 20 mM sodium-phosphate 
buffer instead of water. Phosphate strongly stabilized the beta-sheet of KLK in all our 
experiments (Figure 8C), whereas the random coil conformation of KPK was not affected by 
phosphate (Figure 8D). In contrast to our previous findings it was not possible to induce an 
alpha-helix by addition of TFE (Figure 8E). Up to 60% TFE were administered without 
apparent conformational transition from beta-sheet to alpha-helix (Figure 8F).  
 
4.1.2. Interaction of KLK with various membrane systems 
 
Cationic peptides in general elicit their antimicrobial activity by binding to membranes and 
changing the membrane stability and permeability. One possible mechanism is the formation 
of pores through which certain constituens are released. Alvarez-Bravo et al. showed that 
administration of 5 µg/ml KLK leads to release of glucose from artificial lipid vesicles 
(Alvarez-Bravo et al., 1994). The latter experiment is rather artificial as natural membranes 
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Figure 8. Conformational propensities and stabilization
(A) In the presence of 1 % SDS KLK (black) but not KPK (grey) demonstrates typical β-sheet
conformation on a Circular dichroism spectrum. (B) KLK (black) but not KPK (grey) has α-helical
propensity in presence of  20% TFE. (C) Phosphate buffer stabilizes β-sheet structure of KLK (grey). 
(D) KPK is not affected by presence of phosphate buffer. (E) Phosphate buffer prevents TFE-induced
alpha-helix formation of KLK even at higher amounts of TFE (F). 
 have integral proteins that could affect KLK activity. Therefore, we tested the standard 
concentration of 10 nmole/ml (16 µg/ml) KLK in a more natural system. 
 
4.1.2.1. Interaction of KLK with SMPs 
To test whether KLK and KPK alter membrane stability or permeability, we used the 
established system of yeast sub-mitochondrial particles (SMPs) previously established in our 
laboratory (Nowikovsky et al., 2004; Froschauer et al., 2005). SMPs are derived from the 
inner mitochondrial membrane of the yeast Saccharomyces cerevisiae by sonication. 
Membrane proteins are present but directed inside out. Various ion selective dyes such as 
PBFI can be enclosed into these vesicles. The basal fluorescence emmission profile of PBFI is 
altered in the presence of potassium. When SMPs derived from wild type mitochondria are 
loaded with PBFI and potassium is administered to the outside, the K+/H+ exchanger protein 
Mkh1p leads to antiport of potassium through the membrane and a subsequent change in the 
fluorescence of PBFI. Knock out of Mkh1p (mkh1Δ) completely abolishes potassium-flux 
through the tight membrane. Only the disruption of the membrane by detergents or pore-
forming peptides would allow contact between potassium and PBFI. Therefore, this system 
allowed the observation of KLK and KPK effects on a natural membrane. 
 
4.1.2.1.1. KLK interacts with the potassium-selective dye PBFI 
Initial experiments revealed a unique interaction between the ion-selective dye PBFI and 
KLK. The peptide increases the fluorescent signal-intensities emmitted by both the unbound 
and the bound fractions (excitation curve at 380 nm and 340 nm, respectively), but the 
increase of the unbound fraction is considerably larger and therefore leading to a decline in 
the ratio curve (Figure 9A). A following addition of potassium reverted the effect of KLK 
suggesting that K+ binds PBFI with higher affinity than KLK. Thus, further administration of 
KLK to a potassium-saturated system did not induce a comparable shift in fluorescence 
(Figure 9B). The observed phenomenon is specific for KLK as KPK did not exhibit any 
effects on the dye (Figure 9C).  
 
4.1.2.1.2. KLK interacts with vesicle enclosed PBFI without pore formation 
For the next experiments PBFI was entrapped in SMPs derived from wild type and mkh1Δ-
strains (Figure 10A and B). In the wild type situation administration of 150 mM potassium led 
to an immediate Mkh1p driven transport through the SMP-membrane and a subsequent 
interaction with PBFI enclosed in the vesicles. This interaction results in an increase of the 
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Figure 9. Interaction of KLK and its derivative KPK with the K+-selective fluorescent dye PBFI
Fluorescent signal intensities emitted by K+-bound and free PBFI were recorded simultaneously (black 
and light grey curves, respectively). KLK, KPK and KCl were administered at the indicated time 
points. (A) Data recorded with KLK. (B) Observations made with administration of KLK, followed by 
KCl and subsequently by KLK. (C) Results obtained with KPK. Inserts depict the ratio of fluorescence 
given by K+-bound and free PBFI in the same experiments. 
 bound fraction of PBFI (Figure 10A). In the SMPs of the mkh1Δ-strain transport and 
interaction are abolished (Figure 10B).  
In Figure 10C potassium was first added to the SMPs to demonstrate that the vesicles are tight 
(Figure 10C). Subsequent administration of KLK led to the described typical effect on the 
signals demonstrating that KLK gets in contact with the dye enclosed in the vesicle. At the 
same time it is apparent that no pores are formed which would lead to an interaction of 
potassium and PBFI and therefore to a reversion of the KLK effect causing a signal as 
observed in the PBFI control experiment (Figure 9A). As expected, addition of KPK shows 
no effect (Figure 10D). To clarify whether the observed phenomenon is dependent on 
proteins, that are still present in the SMP-system, similar experiments were conducted using 
artificial asolectin vesicles that can also be loaded with PBFI but do not have membrane 
proteins. The loading efficiency of these vesicles is reduced and thus the signal intensities of 
the dyes are not as strong as in SMPs. Nevertheless the results clearly demonstrate that the 
effect of KLK is not dependent on SMP-proteins (Figure 10E).  
 
4.1.2.1.3. Localization of KLK within the SMPs 
Two different possibilities can explain the interaction of KLK with the entrapped dye. First, 
KLK might pass the membrane and accumulate within the vesicules. Second, KLK is 
attracted by the outer and the inner leaflet of the membrane and stays in close contact with the 
membrane. In this case, as the peptide is not diffusing freely, only minor portions of KLK 
would be found within the vesicle. To discriminate between the two possibilities KLK was 
administerd to SMPs which were centrifuged and the supernatant was collected, the pellet 
fraction was sonicated by tip-sonication to release the entrapped material and the pellet 
fraction, the entrapped material and the supernatant were subjected to MALDI-TOF mass 
spectrometry analysis.  
KLK appears as two specific peaks in the MALDI-TOF spectrum (Figure 11A). These peaks 
are found in the supernatant fraction (Figure 11B) and in the pellet fraction that represents the 
membrane of the SMPs (Figure 11D) but negligebly within the vesicles (Figure 11C).  
FITC-labelled KLK was used to confirm these results microscopically. In the presence of 
SMPs KLK accumulates in the vicinity of the vesicles and forms large aggregates (Figure 
11E). After centrifugation a small portion of SMPs and KLK-FITC can be observed in the 
microscope (Figure 11F). When the SMPs are sonicated, KLK-FITC predominantly stains the 
membrane fraction (Figure 11H) and no signal is found in the entrapped material (Figure 
11G). Although this method has limited ability for quantification, it is sufficient to estimate 
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Figure 10. Effect on KLK and KPK on SMP-vesicles
Wild type or mkh1Δ sub-mitochondrial particles (SMPs) and large unilamellar asolectin vesicles were 
loaded with the K+-sensitive fluorescent dye PBFI. KCl and KLK/KPK were administered at the 
indicated time points. Fluorescent signals emitted by K+-bound and free PBFI were recorded (black 
and light grey curves, respectively). SMPs isolated from wild type DBY747 (A) or DBY747 mkh1Δ
(B) S. cerevisiae strains. Effect of KLK (C) and KPK (D) on PBFI-loaded mkh1Δ SMPs. Effect of 
KLK on PBFI-loaded asolectin vesicles (E). 
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Figure 11. Localization of KLK within SMPs
Mkh1Δ SMPs were incubated with 20 nmole/ml KLK (A-D) and KLK-FITC (E-H) for 30 min on ice 
and centrifuged. Supernatant was saved and the vesicles washed extensively with reaction buffer. SMPs
were then mechanically disrupted by tip-sonication and centrifuged. Supernatant (C, G) and pellet (D, 
H) together with the supernatant from the first centrifugation (B, F) and a buffer control with KLK 
added (A, E) were analysed for KLK and KLK-FITC content by MALDI-TOF mass spectrometry and 
fluorescence microscopy, respectively.
 distribution of the peptide in the examined samples. These results together suggest that the 
majority of KLK associates with or intercalates into the membrane of the SMPs and is not 
generally distributed within the vesicles. Our experiments also reveal that the peptide 
associates with the membrane in a way that it is accessible for reactive material, like the PBFI 
dye, enclosed in the vesicle. 
 
4.1.2.2. KLK affects erythrocyte membrane fluidity 
Because of the relatively simple, homogeneous and well described membrane model offered 
by human erythrocytes and erythrocyte ghosts (Dodge et al., 1962), we tested the effect of 
KLK and KPK on the osmotic fragility of these cells as well as on fluidity parameters.  
Untreated, KLK- or KPK-treated erythrocytes were exposed to increasing hydrophobic 
environment (Figure 12A). Haemoglobin release was detected by measuring optical density at 
540 nm. The osmotic resistance of both KLK and KPK treated samples was identical to the 
control (Figure 12A). 
Diphenylhexatriene (DPH) is a fluorescent probe that incorporates into the hydrophobic core 
of  biological membranes. The fluorescent probe trimethylammonium-DPH (TMA-DPH) is a 
more hydrophilic derivative and incorporates into the outer parts of lipid bilayers. The 
incorporation into the plasma membrane is dependent of membrane fluidity or viscosity and 
leads to detectable fluorescence of the dye at 425 nm. Therefore, DPH- or TMA-DPH-
dependent anisotropy measurements represent the state of fluidity of the hydrophobic core 
and surface compartment of the membrane, respectively (Bogner et al., 2002). 
Our experiments revealed that KLK strongly increases both DPH and TMA-DPH dependent 
anisotropy indicating increased micro-viscosity or decreased membrane-fluidity of both the 
inner and the outer core of the lipid bilayer (Figure 12B).  
None of these microviscosity parameters were affected when the samples were treated with 
KPK (Figure 12B). 
 
4.1.2.3. Ultrastructural effects of KLK on various membranes  
One aspect of the biocydal effects of AMPs is the binding to membranes where the induce 
pore formation or changes of the membrane structure which finally leads to lysis of the 
pathogen (Hof et al., 2001). The observed effects of KLK on various membranes and the 
decrease of fluidity in erythrocyte-ghosts let us speculate whether these effects are also 
associated with ultra-structural changes of the membranes. Therefore, the membrane-structure 
 of KLK or KPK treated SMPs was compared with untreated samples in the transmission 
electron microscope (TEM).  
 
4.1.2.3.1. Small mitochondrial particles 
Control vesicles are membrane-boarded structures with a constant size of 0.1-0.3 nm in 
diameter, they lack electron dense content and due to the preparation, the vesicles are 
occasionally surrounded by membrane fragments resulting in a debris-like background.  
KLK induced a striking reduction in vesicle size with simultaneous enrichment of the debris-
like background material. The vesicles appeared ragged-edged and often with reduction of 
osmophilicity in their membranes (Figure 13A). Larger magnifications show generally 
disordered bilayer structure, a morphology that was characteristic of nearly all vesicles in the 
field of view (Figure 13B). None of these effects were observed in KPK treated samples 
(Figure 13A) 
 
4.1.2.3.2. Dendritic and ECV-cells 
After revealing these KLK-effects the next important step was to administer the peptide to 
dendritic cells (DCs). DCs represent professional antigen presenting cells (APCs), the primary 
target cells of IC31TM. 100 nmole/ml KLK were administered to human monocyte derived 
DCs. After 15 minutes the semi-adherent cells were centrifuged and fixed with 
glutaraldehyde. In the electron microscope KLK-treated DCs appeared with a changed 
morphology including protrusion of the dendrites (Figure 14A).  
In a co-operation with the group of Gerhard Schütz at the Kepler University of Linz, we 
further analysed the membrane structure after KLK treatment in a well-established cell 
system. ECV endothelial-cells were treated with a high dose (100 nmole/ml) KLK for 5 
minutes before they were fixed with glutaraldehyde. KLK-treated ECV cells exhibit vesicle-
enriched periphery of their cytoplasm as well as yet unidentified filamentous depositions at 
the cell surface (Figure 14B).  
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Figure 12. Effect of KLK and KPK on human erythrocyte membranes
Human erythrocytes were exposed to media with increasing osmolarity and the effect of KLK and KPK 
was recorded on the osmotic resistance as measured by haemoglobin release at OD of 540nm (A). 
Effect of KLK and KPK on the fluorescent anisotropy of DPH- and TMA-DPH-loaded erythrocyte 
ghosts (B). For each sample the fluorescence was corrected for the scattering effect of unlabeled ghosts. 
Asterisks represent p-values, p < 0,001.
control KPK KLK A
control KLK 
B
Figure 13. KLK effects on SMP membrane ultrastructure
(A) Untreated control and KLK- or KPK-treated mkh1Δ SMPs were incubated for 30 min on ice and 
centrifuged. Pellets were processed for electron microscopic analysis. Black arrowheads indicate larger 
vesicles with electron dense membranes, while white arrows show smaller, ragged-edged vesicles with 
less osmiophylic membranes. Bar corresponds to 0.1 µm. (B) Larger view of transmission electron 
micrographs obtained from control vs. KLK-treated mkh1Δ SMPs. White arrowheads indicate widths 
of control (upper panel) and a KLK-treated (lower panel) SMP membrane-bilayers. Comparison of 
larger magnifications in the inserts allows judgement of membrane rearrangement caused by KLK.
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Figure 14. Ultrastructural effects of KLK on cells
Transmission electron micrograps of untreated control or KLK/KPK treated dendritic and ECV-cells. 
Black arrowheads indicate protrusion of dendrites (A). KLK-treated ECV cells exhibit vesicle enriched
periphery of their cytoplasm as well as yet unidentified filamentous depositions at the cell surface. (B).  
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Figure 15. Aggregate formation of KLK and ODN1a
(A) Aggregate formation by KLK and ODN1a was confirmed using a gel retardation assay. ODN1a 
(lane 2), KLK/ODN1a (lane 3) and KPK/ODN1a (lane 4) were loaded on a 2% agarose gel. 
KLK/ODN1a-aggregates did not migrate into the gel and were washed out of the slot during the run. 
(B) Particle size distribution measurements of KLK/ODN1a aggregates (black line) and KPK/ODN1a 
aggregates (grey line) in water using a Malvern Mastersizer 2000.
KPK-ODN1a aggregates = water control
KLK-ODN1a aggregates
 4.1.3. Complex formation of KLK with ODN1a 
 
IC31® was demonstrated to form a stable depot at the injection site (Schellack et al., 2006). 
Before IC31® is injected the components are mixed and aggregate. We assumed that the 
different conformational properties of KLK and KPK might be an important factor in these 
complexes and this could explain why KLK but not KPK is able to form the stable depot at 
the injection site.  
In an initial experiment 10 µg ODN1a were mixed where indicated with 40 µg KLK or KPK 
and loaded on a 2% agarose-gel. KLK readily aggregated with ODN1a and completely 
inhibited the movement of ODN1a into the gel. (Figure 15A). In comparison, administration 
of KPK did not lead to retardation.  
To measure the size of the observed aggregates, the Malvern Mastersizer 2000 was used. 
According to the Mie-theory the scattering of electromagnetic radiation by spherical particles 
can be used for characterization of particle-sizes (Stebbing et al., 2008).  
In Figure 15B, the area below the graph represents the amount of complexes with the 
indicated size. KPK showed a peak similar to the water control and thus did not form particles 
or aggregates with ODN1a (Figure 15B). KLK on the other hand exhibited a non-
homogenous size distribution. Four distinct groups were observed (Figure 15B). The smaller 
complexes had a diameter below 70 µm, while considering the area below the graph, only one 
or two complexes with a size of 500 µm and 800 µm formed the last two fractions.  In these 
measurements the majority of the complexes had sizes between 70 and 250 µm, in agreement 
with the microscopic examinations showing that most ODN1a-Cy5/KLK aggregates had a 
diameter below 100 µm (see following chapters, e.g. Figure 17, arrow 1). 
 
 
 4.2. Uptake and distribution of the components of 
IC31® in dendritic cells 
 
The previous experiments revealed strong membrane interacting properties of KLK, which 
can form aggregates with ODN1a. Therefore we assumed that KLK might elicit additive 
effects on ODN1a function in vivo. The TLR9 agonist has to be taken up into the target cells, 
the dendritic cells, and interact in specific compartments with the receptor. TLR9 itself resides 
in the ER and is relocated to the lysosomal compartments upon stimulation with CpG-DNA 
(Latz et al., 2004). With the following experiments we aimed to shed more light on the uptake 
routes of ODN1a and KLK and clarify their roles in interplaying as an adjuvant. 
 
4.2.1. The cellular fate of ODN1a 
 
ODN1a is thought to be the main stimulus for the activation of dendritic cells by IC31®. Thus 
a clear picture of the fate of ODN1a in an in vitro and in vivo situation is essential for the 
understanding of the adjuvant effects. Therefore we were interested in studying the influence 
of KLK on ODN1a uptake and the distribution of the nucleotide within the cell. 
 
4.2.1.1. KLK enhances ODN1a uptake by dendritic cells 
To test whether the described membrane interactive properties of KLK show effects at the 
cellular level, ODN1a was labelled at the N-terminus with Cy5 as described elsewhere 
(Schellack et al., 2006), it was pre-mixed with KLK/KPK, diluted in medium and added to 
various cell types.  
We show that KLK but not KPK enhances the uptake of ODN1a in immature human 
monocyte derived DCs (Figure 16A) and immature mouse bone marrow derived DCs (Figure 
16B). The uptake can be blocked by incubation of the cells on ice (Figure 16B). Low 
temperature affects the cell membrane fluidity and thus the membrane turnover. This indicates 
that ODN1a has to be taken up via the classical endocytic routes and KLK is not working as a 
cell penetrating peptide that carries the nucleotide through the membrane into the cytoplasm.  
The uptake of ODN1a is rapid as it can be found in dendritic cells already after 5 minutes, but 
the signal intensity of ODN1a-Cy5 increases over time with a peak at about 60 minutes 
(Figure 17). Then the staining slowly disappears within the next hour as ODN1a is probably 
degraded. When both components of IC31® are mixed and added to the cell we can find 
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Figure 16. KLK enhances ODN1a uptake by dendritic cells
(A) ODN1-Cy5 (red) were mixed with KLK/KPK and administered to immature human monocyte
derived DCs. As a control ODN1a was added directly to the cells. Cells were fixed after 60 minutes
and nuclei were labelled with DAPI (blue). (B) ODN1a-Cy5 (red) uptake by immature mouse bone 
marrow derived DCs in the presence of KLK or KPK at room temperature (RT) and 0°C. White bars 
represent 10 µm. 
KL
K
KP
K
RT Ice
Mouse bone marrow derived DCs
 complexes in the microscope that are comparable in size to the measured particles in the 
master-sizer (~ 100 µm). The majority of these aggregates associate with one or more DCs in 
the culture and often one large complex covers many cells (Figure 17, black arrowhead).  
In various experiments ODN1a seems to appear in the nucleus. This is a well-known artefact 
of the fixation procedure. The PFA treatment enables ODN1a to pass through the nuclear 
membrane where it is attached to DNA-binding proteins like histons. (Lundberg and 
Johansson, 2002). The nuclear localisation is not seen during live-cell imaging (see below).  
 
4.2.1.2. Dynamics of KLK/ODN1a complex association at the cell surface 
We were interested to see, how KLK/ODN1a aggregates interact with the cell surface over 
time. Therefore we monitored these complexes with live cell fluorescent confocal time-laps 
imaging. These experiments revealed that the interaction between cell membrane and the 
KLK/ODN1a-complex is highly dynamic. The complex gets in contact with sites at the 
membrane. Interestingly not every contact leads to a stable interaction. As shown in Figure 
18, a complex approaches the tip of a dendrite where we observe the formation of a stable 
interaction that lasts for more than 60 minutes (Figure 18, black arrowhead). Alongside of the 
dendrite another complex gets in contact with the membrane but a stable interaction is not 
formed and the complex leaves the contact site (Figure 18, white arrowhead). At the tip of the 
same dendrite another interaction is formed (Figure 18, black arrow).  
  
4.2.1.3. ODN1a is taken up into early and late endosomes 
Based on earlier observations we assumed that the uptake of ODN1a is energy dependend and 
most likely an endocytotic process (Figure 16B). To further proof this, we treated DCs with 
ODN1a-Cy5 and an antibody against human transferrin receptor (TfR), an early endosomal 
marker which is known to be internalized via a clathrin-mediated pathway (Duarte C Barral, 
2008), and with an antibody against human Lamp1 to visualize late endosomes. The well 
studied CpG-DNA (Heeg et al., 2008) was used as a positive control as this TLR9 ligand has 
been shown to locate to these compartments (Latz et al., 2004). Figure 19 shows that ODN1a-
Cy5 localizes with both TfR and Lamp1 positive structures, suggesting ODN1a distribution in 
both early (A) and late endosomes (B), similarly to CpG-DNA.  
 
4.2.1.4. ODN1a is localized in the endoplasmic reticulum 
Our studies indicated that besides various endosomal localizations ODN1a is clearly seen in 
compartments other than the endosomes (Figure 19). One location is perinuclear and we 
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Figure 17. Time course of ODN1a uptake by dendritic cells
ODN1a-Cy5 (red) and KLK were administered to immature mouse bone marrow derived
DCs. After indicated time points the cells were fixed and the nuclei were stained with DAPI 
(blue). Cells were monitored by laser confocal imaging. White arrowhead indicates an 
example of KLK/ODN1a-aggregate covering cells. 
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Figure 18. Interaction dynamics of KLK/ODN1a complex with dendritic cells
Live cell laser confocal imaging of human monocyte deriveded dendritic cells demonstrating the
dynamics of ODN1a/KLK-aggregate interaction. ODN1a-Cy5 (red) was mixed with KLK and 
administered to the cells. At the tip of a dendrite stable interactions are formed (black arrowhead; black
arrow) while alongside of the dendrite a complex leaves the contact side (white arrow). ER-tracker
(green) was added to stain the endoplasmic reticulum.  
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Figure 19. Detection of ODN1a in early and late endosomes
Immature human monocyte derived dendritic cells were exposed to ODN1a-Cy5/KLK or CpG-Cy5 for
60 minutes. Cells were fixed and stained with antibodies against (A) the early endosomal marker TfR
(green) or (B) the late endosomal marker Lamp1 (green). Co-localization (wite arrows) was revealed by
laser confocal imaging.
 therefore stained DCs with the drug conjugate glibenclamide BODIPY® FL that binds to the 
sulphonylurea receptor of ATP-sensitive K+ channels, prominent proteins of the ER. The 
staining of the ER with this ER-tracker takes up to 30 minutes. Live-cell imaging reveals this 
delay as the signal intensity of the tracker increases over time. In fixed cells we demonstrated 
that the residual ODN1a that is found in the dendritic cells is distributed within the ER of 
human monocyte derived dendritic cells and mouse bone marrow derived dendritic cells, 
similarly to CpG-DNA (Figure 20). Using live cell laser confocal imaging ODN1a/KLK-
complexes could be detected at the cell surface (Figure 21, black arrowheads). We observed 
that the red ODN1a signal gradually turns yellow as ODN1a was taken up into the cell and 
co-localizes with the ER (Figure 21, black arrow).  
 
4.2.1.5. ODN1a colocalizes with TLR9 but its uptake does not require TLR9  
ODN1a is a TLR9 agonist. Latz et al. have demonstrated that TLR9 resides in the ER but 
relocates to the so called tubular lysosomal compartments in the presence of CpG-DNA (Latz 
et al., 2004). We have seen ODN1a in endosomes as well as ER but wanted to have a direct 
proof for ODN1a/TLR9 colocalization. With newly available antibodies against human and 
mouse TLR9 we showed that ODN1a clearly colocalizes with TLR9 positive structures 
(Figure 22A).  
Uptake of ODN1a into dendritic cells was independent of the presence of the receptor. 
Similarly to wild type cells DC from TLR9-/- mice took up comparable amounts of ODN1a 
within 45-60 minutes (Figure 22B).  
 
4.2.1.6 ODN1a uptake of various cell types 
KLK interacts with ODN1a and with the cell membrane. Based on our results that KLK 
stimulates ODN1a uptake most likely via endocytosis, we assumed that the rate of 
endocytosis or the membrane turnover is important in the ODN1a uptake process. Immature 
dendritic cells are known as professional APC and exhibit compared to other cell types an 
increased uptake of material via endocytosis (Sallusto et al., 1995). In accordance with this, 
when experiments were performed using Hela-, C2C12- and CaCo-cells we found the typical 
binding of the ODN1a/KLK-complex to the cell surface but we did not observe an uptake of 
ODN1a (Figure 23A). The basal endocytosis-rate of these cells did most likely not allow the 
internalization of enough ODN1a to be visible in our experiments.  
Macrophages, however, cells of the immune system that are specialized to take up antigens 
from the environment, took up ODN1a regardless of the presence or absence of KLK (Figure 
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Figure 20. ODN1a uptake into the endoplasmic reticulum
Immature human monocyte derived and immature mouse bone marrow derived DCs were stained with
ER-tracker (green) and exposed to ODN1a-Cy5 (red) and KLK or CpG-Cy5 in absence of KLK. Cells
were fixed and nuclei were stained with DAPI (blue). Co-localisation was revealed using laser confocal
imaging. 
Figure 21. Live cell confocal imaging of ODN1a uptake into the ER
Time-lapse fluorescence confocal imaging of immature human monocyte derived DC that encounters
ODN1a/KLK-aggregates (black arrowheads) and internalizes ODN1a into the endoplasmic reticulum
stained with ER-tracker (green). Arrow indicates the cytoplasmic region of the cell were ODN1a co-
localizes with the ER-compartment.
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Figure 22. ODN1a colocalizes with TLR9, but ODN1a uptake is TLR9 indipendent
(A) Immature mouse bone marrow derived DCs were exposed to ODN1a-Cy5 (red) and KLK and 
stained with antibodies against TLR9 (green) after fixation. Co-localisation was monitored by laser
confocal imaging. On the right panel the contours of a DC are marked with a white dotted line. 
Arrowheads indicate TLR9 and ODN1a double positive structures, arrows point to ODN1a positive 
vesicles. (B) Immature mouse bone marrow derived DCs from wild type and from TLR9-/- were
exposed to ODN1a-Cy5 (red) and KLK for 60 minutes. After fixation the nuclei were stained with
DAPI and samples were analysed by laser confocal imaging. 
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Figure 23. ODN1a uptake of various cell types
(A) ODN1a-Cy5 (red) and KLK were administered to HELA-, C2C12-, CaCo- and HEK-cells for 60 
minutes before the cells were fixed nuclei were stained with DAPI (blue). Cells were monitored by
laser confocal imaging. (B) ODN1a-Cy5 was administered to the mouse bone marrow derived
macrophages in presence or absence KLK/KPK. After 60 minutes the cells were fixed and the nuclei
were stained with DAPI. Bars represent 10 µm.
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 23B). Using the endosomal marker FM1-43 we could proof a clear localization of ODN1a 
endosomal vesicles of macrophages (Figure 24).  
 
4.2.2. The cellular fate of KLK 
 
KLK is essential for the formation of a stable complex at the injection site. This depot 
formation is a key factor in the stimulation of the immune system. Further, as demonstrated 
above, KLK also increases the endocytic uptake of ODN1a into dendritic cells. We have seen 
that KLK/ODN1a-complexes interact with the cell membrane and are then taken up and that 
ODN1a-Cy5 can be found in early and late endosomes as well as in the endoplasmic 
reticulum. As a next step we examined the fate of KLK during this process by using FITC-
labelled peptide. 
 
4.2.2.1. KLK is not taken up into DCs 
Interestingly when administered to DCs we can microscopically not observe any uptake of 
KLK into the cells. KLK readily stains the plasma membrane but is not found within 
endosomes or other cytoplasmic structures (Figure 25A).  
In a further experiment we added a mixture of KLK-FITC/ODN1a-Cy5 to the cells. 
Complexes appear yellow and are found in close contact with the cell membrane (Figure 25B, 
arrows). During the process of endocytosis the complex dissociates and only ODN1a is taken 
up into the cell (Figure 25B, arrowheads).  
To prove this contact loss between the adjuvant components upon internalization of the 
nucleotide, fluorescence resonance energy transfer (FRET) experiments were performed using 
TAMRA-labelled KLK and Cy5-labelled ODN1a. This microscopy technique measures the 
proximity of two fluorophores and is often used to determine when and where two or more 
biomolecules interact within their physiological surroundings. As energy transfer occurs over 
distances of 1-10 nm, a FRET signal corresponds to a particular location of two biomolecules. 
The measurement offers an additional distance accuracy surpassing the optical resolution 
(~0.25 mm) of the light microscope. The average FRET value between ODN1a-Cy5 and 
KLK-TAMRA on a glass slide was 8.8% (Figure 25C, Bar 1). Here, the FRET value was 
concentration dependent. At a concentration ratio (cr) of ODN1a-Cy5 to KLK-TAMRA of 
<10 the FRET value was 6.9 %, at cr > 10 10.8 %, (data not shown). No FRET was observed 
between KLK-TAMRA and Cy5 only (fluorochrome without the nucleotide), suggesting that 
the FRET shown in Figure 25C was not due to the high concentration of the labelled 
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Figure 24. Comparison of endosomal ODN1a uptake by dendritic cells and macrophages
Immature human monocyte derived DCs and mouse bone marrow derived macrophages were exposed
to ODN1a-Cy5 (red) in presence of KLK (DCs) or ODN1a-Cy5 alone (macrophages). Endosomes
were stained using FM1-43 (green). After 60 minutes cells were fixed and nuclei were stained with
DAPI (blue). Samples were analysed by laser confocal imaging. White arrowheads indicate ODN1a-
Cy5 co-localizing with FM1-43. Bars represent 10 µm. 
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Figure 25. KLK is not internalized by dendritic cells
(A) KLK-FITC (green) was administered to immature human monocyte derived DCs and cells were
monitored with fluorescence microscopy. (B) ODN1a-Cy5 (red) was mixed with KLK-FITC (green) 
and administered to immature humane monocyte derived DCs.  Cells were fixed and the nuclei were
stained with DAPI (blue). Samples were analysed using laser confocal imaging. Arrows point to KLK 
and ODN1a double positive complexes. Arrowheads indicate ODN1a positive vesicles. (C) Jurkat T 
cells were exposed to ODN1a-Cy5 and analyzed for FRET as described in Material and Methods. 
ODN1a-Cy5 and KLK-TAMRA (1), Cy5 and KLK-TAMRA on a glass slide (2), extracellular FRET 
signal average efficiency (3). (D) Fluorescent images of a Jurkat T cell and a mouse bone marrow
derived dendritic cell channeled to detect ODN1a-Cy5 and KLK-TAMRA emission signals. The
contour of the mouse DC is outlined in the figure for better orientation.
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 components. In a next step, the FRET value between nucleotide and peptide was measured in 
presence of Jurkat T cells. After incubation of the cells with both substances, FRET was 
calculated in the extracellular space and within the cells. In the extracellular space the average 
FRET of 7 % was similar to the measurements without cells (6.9 % for cr <10; Figure 25A, 
Bar 3). Since no intracellular FRET intensity was observed, we attempted to obtain 
fluorescent images of Jurkat T cells exposed to ODN1a-Cy5 and KLK-TAMRA. As 
demonstrated for other cells (Figure 23A), no uptake of ODN1a-Cy5 could be shown. This 
result explained why no FRET signal could be measured within these cells. Despite of 
multiple attempts, it was not possible to detect FRET using dendritic cells, but fluorescence 
imaging of these cells clearly revealed ODN1a localization within the cell and – similarly to 
Jurkat T cells – KLK remained outside (Figure 25D).  
Together these data favour the assumption that ODN1a is internalized by DCs while KLK 
remains localized at the cell periphery. 
 
 
 
 
 4.3. Antigen uptake 
 
IC31® is used as an adjuvant to stimulate the immune reaction against co-injected antigens 
and to modulate this response to the desired way. As we have already dissected the fate of the 
two adjuvant-components, our attention turned to the antigen uptake. 
 
4.3.1. OVA-FITC 
 
Fritz et al. presented clear data that KLK entraps the antigen at the injection site and enhances 
the adaptive immunity to co-injected antigens (Fritz et al., 2004). Our aim was to examine, 
whether KLK stimulates the uptake of the model antigen OVA-FITC (FITC labelled 
Ovalbumin) in comparison with ODN1a-Cy5 into DCs. 10 µg/ml OVA-FITC was 
administered directly or after mixing with 10 nmole/ml KLK to immature mouse bone 
marrow derived DCs. The aggregation of KLK and OVA-FITC subducts free antigen from 
the medium and therefore the general staining of the cells with OVA-FITC is higher in KLK-
free samples. It is seen that in special proximity to KLK/OVA-FITC aggregates, DCs show 
increased OVA-FITC uptake (Figure 26A).  
To compare the uptake of OVA-FITC and ODN1a-Cy5, both were premixed with KLK and 
added to the cells. Interestingly, although the antigen and the nucleotide show a vesicular 
localization after 1 hour and some vesicles contain both fluorescent components, not all are 
colocalizing (Figure 26B, white and black arrows). This suggests that the uptake of ODN1a 
and antigen are mediated by identical as well as distinct internalization routes. 
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Figure 26. Simultaneous uptake of antigen and ODN1a by dendritic cells
Laser confocal images of immature mouse bone marrow derived DCs. OVA-FITC (green) 
was administered in presence or absence of KLK (A) or in presence of ODN1a-Cy5 (red) and 
KLK(B). After 60 minutes the cells were fixed and the nuclei were stained with DAPI (blue). 
White arrowheads point to ODN1a and OVA double positive, white arrows to OVA and black
arrows to ODN1a positive structures.
OVA-FITC + ODN1a-Cy5 + KLK
 5. Discussion 
 
In the recent years numerous studies have been published concerning the profound immuno-
stimulatory effect of IC31® (Agger et al., 2006; Schellack et al., 2006; Lingnau et al., 2007; 
Kamath et al., 2008; Riedl et al., 2008). Although, broader knowledge has become available 
about the immuno-modulatory mechanisms of the TLR9 agonist ODN1a, our understanding 
of how the peptide component KLK contributed to the immunological effects of IC31® 
remained elusive. Therefore, our first aims were to shed light on the physico-chemical 
parameters of KLK, including membrane interacting properties, conformational propensities 
as well as its direct effects on various model membrane systems. It has been shown that 
ODN1a, when it is injected alone dissipates quickly from the site of injection in mice. KLK is 
necessary and sufficient to form a stable depot with ODN1a at the injection site (Schellack et 
al., 2006). Although as positively charged as KLK, the immunologically inactive derivative 
KLKLLPLLKLK (KPK) does not induce this depot formation with ODN1a. It is therefore 
likely that the different effects are caused by alternative peptide structures which might be 
linked to the environment-dependent conformational properties of the peptide.  
An equally exciting question was to understand how KLK mediated the delivery of ODN1a 
into the primary target cell of IC31®. Internalization of ODN1a by dendritic cells is 
considerably up-regulated by KLK, a phenomenon that was cell specific, peptide specific and 
linked to endocytotic activity. Thus, we have carefully dissected mechanisms linked to 
interaction of KLK/ODN1a comlex with DCs, to endocytotic uptake routes, cytoplasmic 
distribution and receptor-ligand binding.   
 
 
 
 
 
 
 5.1. Conformational properties of KLK 
 
Using circular dichroism measurements we observed, that comparable to many other peptides 
KLK and KPK exhibited a random coil structure in water (Seelig, 2004). Administration of 
the detergent SDS leads to immediate transition of KLK to a β-sheet conformation (Figure 
8A). To create a membrane-mimicking environment, SUVs containing uncharged lipids, were 
included in the measurement. KLK readily transited to a β-sheet conformation (Figure 7B). 
Having the length of KLK in mind, we considered this structure as a consequence of 
intermolecular interactions. This β-sheeted molecular aggregate most probably represents the 
conformational state in which KLK forms large complexes with ODN1a (see below). 
Considering the well-known charge attraction of cationic peptides to negatively charged 
moieties of membranes, increasing amounts of negatively charged SUVs were administered. 
In this experiment, an additional, β-sheet to α-helical conformational-transition of KLK could 
be observed (Figure 7C). After administration of the same concentration of uncharged SUVs, 
KLK did not exhibit an alpha-helical conformation (data not shown). This supports a three-
step molecular recognition mechanism similar to that suggested for the main peptide 
component of Alzheimer plaques, βAP (1-40) (Terzi et al., 1997; Meier and Seelig, 2007). In 
the absence of lipids the βAP peptide displays a random coil conformation. Administration of 
unilamellar vesicles composed of neutral POPC and negatively charged POPG (3:1) to βAP 
(1-40) induces a dramatic spectroscopic shift leading to a CD-spectrum with 70% β-structure. 
As for KLK, a second transition is observed if increasing amount of negatively charged POPG 
are added (Terzi et al., 1997). The middle leucine-to-proline substitution in KPK completetly  
abolished the formation of conformational transitions (Figure 7 and 8). To further analyze 
alpha-helical propensity of KLK, 2,2,2-trifluoroethanol (TFE) was administered to the 
peptide. TFE was demonstrated to stabilize alpha helical structures in proteins and peptides 
(Goodman et al., 1969). After administration of TFE, KLK readily showed a direct transition 
from random-coil to alpha-helix, indicating a high potential to form a helix, whereas KPK 
was not affected by the addition of TFE (Figure 8B).  
We assume that our CD measurements detect equilibria between the possible conformations 
at a given condition. Hydrophobic environment or administration of TFE shifts this 
equilibrium towards β-sheet and α-helix, respectively. Further, we demonstrated that 
phosphate buffer strongly stabilized the beta-sheet conformation of KLK in water and in the 
presence of TFE (Figure 8C and 8F). This effect needs to be studied in more detail. In any 
 case, we were able to demonstrate various conformational statuses of KLK and showed that 
this peptide can quickly switch its conformational properties upon various environmental 
stimuli. 
 
5.2. Membrane interacting properties of KLK  
 
Due to their positively charged, amphipathic structures, a fundamental component of the 
mode of action of cationic antimicrobial peptides, such as KLK, was proposed to be their 
membrane-active property. Using sub-mitochondrial particles (SMPs) we demonstrated that 
KLK interacts with membrane vesicles without pore formation (Figure 10C). Mass 
spectrometric and microscopical analysis of the vesicular sub-fractions indicated that KLK 
preferentially stayed associated with the vesicular membrane (Figure 11). As SMPs harbour 
various inner-mitochondrial membrane proteins on their surface, it was important to study, 
whether these proteins play a role in the membrane-interacting properties of KLK. Alvarez-
Bravo et al. demonstrated lytic activity of KLK measuring glucose-release from artificial 
liposomes (Alvarez-Bravo et al., 1994). In our experiments we used giant unilamellar vesicles 
derived from asolectin lipids by dialysis. As observed in the SMP-experiments, we found that 
the interaction of KLK with the artificial membrane occurs without release of vesicular 
content (Figure 10E). Therefore, membrane interaction of KLK is independent of membrane 
proteins and receptors. 
Because of the relatively simple, homogeneous and well described membrane model offered 
by human erythrocytes and erythrocyte ghosts (Dodge et al., 1962), we tested the effect of 
KLK and KPK on the osmotic fragility of these cells as well as on their fluidity parameters. 
Erythrocytes and erythrocyte ghosts possess highly negatively charged sialic acid-based 
carbohydrate moieties (Varki, 2009) and represent therefore an ideal model to study the 
earlier proposed general strong charge attraction-based mechanisms in KLK action. 
Anisotropy-measurements of human erythrocyte ghosts revealed a strong effect of KLK but 
not KPK as a dramatic increase in DPH and TMA-DPH related anisotropy was seen in KLK 
treated samples (Figure 12B). This effect indicates a strong increase in microviscosity (or 
decrease in fluidity) within both the core and surface compartments of the membrane. On the 
other hand, the osmotic resistance was not affected by the administration of KLK confirming 
the lack of pore formation (Figure 12A).  
One aspect of the biocydal effects of AMPs is the binding to membranes where the induce 
pore formation or changes of the membrane structure which finally leads to lysis of the 
 pathogen (Hof et al., 2001). The observed effects of KLK let us speculate whether these are 
also associated with ultra-structural changes of the membranes. Therefore, sub-mitochondiral 
particles were examined in the electron-microscope after administration of KLK or KPK. 
KLK induced a striking reduction in vesicle size with simultaneous enrichment of the debris-
like background material. The vesicles appeared ragged-edged and often with reduction of 
osmophilicity in their membranes (Figure 13A). A generally disordered bilayer structure 
could be observed in larger magnifications, a morphology that was characteristic of nearly all 
vesicles in the field of view (Figure 13B). None of these effects were observed in KPK treated 
samples (Figure 13A). We further demonstrated that KLK strongly disturbs the membrane 
structure of ECV-cells. Human monocyte-derived DCs, the target cells of IC31® in the 
immune system also show a structural effect upon KLK administration. Here, we could 
observe protrusion of dendrites (Figure 14).  
We assume that KLK is generally attracted to the membrane due to its charge. At the vicinity 
of the membrane and under specific lipid-to-peptide stoichiometric conditions KLK 
undergoes the previously observed conformational transitions and intercalates into the lipid 
bilayer. Taking the length of KLK into consideration, the peptide is too short to span the 
membrane. An alternative model for the interaction is the carpet-model. Here, the AMP 
associates with the membrane surface, parallel to it, with the hydrophilic face oriented toward 
the water phase. The peptide intercalation into the phospholipid head groups corresponds to 
an insertion of a cone-shaped molecule into the membrane (Figure 2E). Similar effects can be 
seen with the yeast Yop1p and Rtn1p (Khandelia et al., 2008). These molecules are important 
regulators of membrane curvature of the endoplasmic reticulum. The application of the 
carpet-model would offer an explanation of the effects seen after KLK administration. 
Unequal distribution of KLK at both sides of the membrane bilayer and the intercalation into 
the membrane could therefore lead to a disturbance of the natural membrane curvature and 
induce a disordered membrane structure as observed in the electron microscope.  
 
5.3. Complex formation of KLK with ODN1a 
 
Due to its backbone, the nucleotide ODN1a is negatively charged. After administration of a 
positively charged peptide we can expect charge interaction and formation of various size 
aggregates in solution. This theory was tested by a gel-retardation assay (Figure 15A). 
Interestingly, although KLK and KPK have the same amount of positively charged amino 
acids KLK but not KPK aggregated with ODN1a (Figure 15). The intermolecular beta-sheet 
 conformational capacity of KLK is the most obvious feature to explain this aggregation 
phenomenon. Thus, the potential of conformational transitions is a precondition for the 
observed complex formation and explains the inability of KPK to aggregate with ODN1a. 
Taking into account the multiple conformational transitions of KLK we speculate that peptide 
and nucleotide accumulate in a colloid-like complex where the β-sheet aggregates between 
ODN1a and KLK in the hydrophobic core are surrounded by random coil molecules towards 
the solvent-sorrounded surface of the aggregate. A dynamic equilibrium is assumed between 
the peptide pools of various conformational stages (Figure 27). 
The determination of the particle size distribution revealed distinct size-fractions of the 
nucleotide/KLK complexes. The majority of the complexes exhibited a size between 70 µm 
and 250 µm. It is important to mention that the aggregates observed in the following 
microscopy experiments show the same diameter and therefore confirm these measurements. 
 
5.4. Interaction of IC31® with dendritic cells 
 
After our initial experiments revealing the structural features of KLK and its membrane 
interacting properties, we were interested to study the fate of the two components of IC31® in 
the presence of the target cells, the DCs. We have demonstrated that the presence of KLK 
increased the uptake of ODN1a into immature human and murine dendritic cells (Figure 16). 
This uptake was energy-dependent, as incubation on ice prevented ODN1a uptake. We 
assumed that the uptake of the peptide was via cellular endocytotic mechanisms. We observed 
rapid accumulation of ODN1a within the cell with a peak at 60 minutes. Afterwards the 
ODN1a signal diminished probably due to degradation of the nucleotide (Figure 17). 
KLK/ODN1a based aggregates accumulate at the cell surface as large complexes spreading 
over numerous cells (Figure 17). Live cell laser confocal fluorescence imaging revealed 
dynamic interaction of the DCs with the complexes in the medium (Figure 18). Some 
complexes stay in close contact with its initial docking site at the DC surface, while others 
detach after staying associated with the cell for various length of time. These observations 
point to a possible dependence on specific membrane regions or even micro-domains to create 
a stable interaction between IC31® and a dendritic cell. Thus we hypothesize that at sites of 
high negative surface charges, the colloid-like complex of KLK and ODN1a is attracted to the 
membrane by the free positive charges of the proximal random coil molecules. These can 
interact with the membrane as demonstrated before and bind the whole complex to the cell-
surface.  
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solvent
solvent
Figure 27. Model of colloid-like aggregate formation of KLK and ODN1a
In presence of ODN1a KLK forms a colloid-like complex in solvent. Structured interaction of KLK 
and ODN1 in the core allows assembly of large aggregates. In the periphery unstructured peptide is 
able to undergo conformational transitions and to interaction with membranes. Between core and 
periphery a dynamic equilibrium exists, enabling aggregate transformation and movement of peptide 
and nucleotide.
 5.5. Cellular uptake of ODN1a 
 
Multiple cellular uptake-pathways exist for the delivery of cargo molecules into the cell. All 
pathways except macrophagy converge at the level of early endosomes (for review see 
Mellman, 1996; Spang, 2009). We demonstrated that ODN1a is taken up via a mechanism 
that route the oligonucleotide to early and late endosomes (Figure 19). ODN1a eventually 
reaches compartments that are positive for TLR9 (Figure 22).  
It has still to be observed whether the uptake is pathway specific. The literature offers at least 
three different possibilities, how ODN1a might be internalized. The function of KLK was 
initially claimed to be dependent on calreticulin (Cho et al., 1999), suggesting a receptor 
mediated uptake of ODN1a bound to KLK via calreticulin that involves macropinocytosis 
(Ogden et al., 2001). On the other hand, it has been demonstrated that the uptake of antigens 
or peptides via macropinocytosis does not necessarily need a specific receptor (Sallusto et al., 
1995), indicating, that the uptake of ODN1a would be receptor independent. Further, we have 
clear evidence that the membrane interacting properties of KLK do not depend on the 
presence of any membrane protein (Figure 10E). Additionally, the co-localization with TfR 
points to the classical route via clathrin coated pits.  
We suggest an alternative model. The membrane interacting properties of KLK assure a long 
lasting attachment of ODN1a at or in close vicinity to the plasma membrane. All mechanisms 
involving membrane turnover would now allow an uptake of the nucleotide. Therefore, the 
uptake is not pathway specific but appears due to general membrane turnover that is 
associated with all endocytic routes. This theory would also explain the localization of 
ODN1a within the endoplasmic reticulum (Figure 20 and 21), which would be contradictory 
to the co-localization in the early endosomes. It has recently been demonstrated that 
phagosomes of macrophages (Gagnon et al., 2002) and dendritic cells (Guermonprez et al., 
2003) fuse during the process of cross presentation with the endoplasmic reticulum.  
Preliminary experiments blocking the dynamine-dependent uptake routes with Dynasore and 
the dynamine independent pathways with chlorpromazine showed that inhibition of the 
specific pathways does not notably abolish the uptake of ODN1a (unpublished data) 
suggesting that ODN1a is taken up via multiple routes. Blocking of one particular uptake 
route might be compensated by the other internalization mechanisms.  
If our assumption is correct, cells with low membrane turnover capacity should exhibit 
decreased ODN1a uptake. Thus, we administered labelled IC31® to various cell types (Figure 
23). HELA-, C2C12-, CaCo- and HEK-cells did not take up the nucleotide component in 
 detectable amounts. Macrophages on the other hand displayed ODN1a uptake. Interestingly, 
the uptake was not dependent on the presence of KLK as it also occurred in untreated and 
KPK-treated samples. The difference between dendritic cells and macrophages regarding 
ODN1a uptake suggests distinct mechanisms of nucleotide uptake. To what extend the cell 
type specific macro-pinocytotic  (Sallusto et al., 1995) and phagocytotic processes (for review 
see Savina and Amigorena, 2007) contribute to the observed difference, remains elusive. 
 
5.6. The cellular fate of KLK 
 
While ODN1a was taken up via various routes, we showed that at least the vast majority of 
KLK stayed attached to the membrane (Figure 25). Thus the peptide-nucleotide complex has 
to dissolve rapidly upon internalization. Taken together with the earlier findings, we assume 
that the alpha-helical conformation is induced at distinct negatively charged loci at the cell 
membrane. Recent data show that KLK is subsequently intercalating with the negatively 
charged inner leaflet of the plasma membrane (Weghuber et al., unpublished data), with a 
simultaneous disruption of the aggregates and internalization of ODN1a into distinct vesicular 
compartments. 
The accumulation of KLK at the inner leaflet of the membrane has been demonstrated to 
induce a halt in the recycling of GPI-anchored proteins and the GEEC-linked pathway 
(Weghuber et al., unpublished data). This may induce a compensatory reaction increasing the 
turnover of other pathways and thus allow the efficient loading of DC cytoplasm with the 
immuno-stimulatory ODN1a.  
 
5.7. Uptake of OVA-protein 
 
It has been demonstrated that KLK induced the loading of APCs with various model antigens 
(Fritz et al., 2004). Therefore, it was our interest to see if we could reproduce this finding in 
our system and whether we can describe an effect of KLK on the antigen uptake of dendritic 
cells. When KLK and OVA-protein are administered to DCs, in the microscope a complex 
formation comparable to KLK/ODN1a can be observed in the cell vicinity. The aggregation 
of KLK and OVA captured free antigen from the medium and therefore the general staining 
of the cells with OVA-FITC is higher in KLK-free samples.  But cells close to KLK/OVA 
complexes took up higher amounts of antigen than the cells in the KLK-free samples (Figure 
 26A). Thus, we were able to demonstrate that, when an antigen is present, efficient uptake is 
possible simultaneously with the KLK induced up-regulation of ODN1a internalization. 
 
5.8. Working model 
 
We suppose that KLK/ODN1a, KLK/OVA and KLK/ODN1a/OVA form a colloid-like 
complex in the vicinity of cells (Figure 27). The complex core is formed by a dynamic 
equilibrium between KLK, ODN1a and antigen. We assume that in contact with the negative 
charged ODN1a KLK exhibits a conformation which allows the formation of large 
aggregates, most probably β-sheet, but conformational transitions and exchange of molecules 
between core and periphery are still possible. At the periphery of the colloid-like complex we 
expect unbound KLK which is able to interact due to conformational changes with cell 
membranes. Upon charge attraction between negative charged cell surface and positive 
charged KLK, the complex attaches to the membrane. Here, KLK undergoes the observed 
conformational transition from β-sheet to α-helix and therefore stabilizes the adherence.   
The long lasting attachment brings ODN1a and antigen in close proximity to the plasma 
membrane. Thus, membrane engulfment and pit formation during general membrane turnover 
leads to uptake of both components via different endocytic routes into early and late 
endosomes as well as tubular lysosomal compartments and the endoplasmic reticulum (Figure 
28). Larger aggregates as shown in Figure 21 might be taken up via phagocytosis explaining 
the localization of ODN1a within the ER (Guermonprez et al., 2003). Other pathways lead to 
uptake into early and late endosomes and allow co-localization with TLR9 in tubular 
lysosomal compartments.  
After KLK induced uptake, ODN1a and OVA do no fully co-localize within the cell 
suggesting identical as well as distinct internalization routes (Figure 26B). This further 
supports our model as we hypothesize that the cargo is not selected but taken up at random.  
The fate of KLK has to be further clarified. Why KLK is not taken up like OVA and ODN1a, 
and how it can avoid engulfment into endocytic vesicles has to be analyzed in more detail.   
Nevertheless, our results make a significant contribution to the better understanding of the 
molecular action of IC31®. For the first time the functions of both the individual KLK and 
ODN1a molecules as well as their combination (IC31®) are understood in more details. With 
the work presented in this thesis IC31® becomes one of the best-understood adjuvants in 
current vaccine research.   
EE
LE
TLC
ER
KLK (random coil)
KLK (b-sheet)
KLK (a-helix)
ODN1a
1
2
3
Figure 28. Model of ODN1a internalization
Colloid-like aggregate of KLK and ODN1a in the cell vicinity (1) is attracted to the plasma membrane 
due to negative surface charge. Conformational transition of KLK stabilizes the interaction of the 
aggregate with the membrane (2). Due to membrane turnover ODN1a is internalized via different 
endocytic routes and localizes within early and late endosomes (EE and LE, respectively), in tubular 
lysosomal compartments (TLCs) and the endoplasmic reticulum (ER). 
Original
 6. Abbreviations 
 
AMP  Antimicrobial peptide 
AP  Adaptor protein 
APC  Antigen presenting cell 
  
CAMP        Cationic antimicrobial peptide 
CCL   Chemokine (C-C motif) ligand  
CCP  Clathrin coated pits 
CCR  Chemokine (C-C motif) receptor 
CD  Clusters of differentiation 
cDC  Conventional dendritic cell 
CI  Clathrin independent 
CLIC  Clathrin- and dynamine-independent carriers 
Cr  Concentration ratio 
CTL  Cytolytic T lymphocytes 
 
DAMP Danger associated molecular pattern 
DC  Dendritic cell 
DNA  Deoxyribonucleic acid 
DPH  Diphenylhexatriene 
DRM  Detergent resistant membrane 
 
ECM  Extracellular matrix 
ECV  Endosomal carrier vesicles 
EE  Early endosome 
ER  Endoplasmic reticulum 
ERAAP ER aminopeptidase associated with antigen processing 
 
FRET  Fluorescence resonance energy transfer 
 
G-CSF  Granulocyte colony stimulating factor  
GEEC  GPI-AP enriched early endosomal compartment 
GEF  Guanin exchange factor 
 GPI-AP Glycosyl phosphatidylinositol-anchored proteins 
 
HIV  Human immunodeficiency virus 
HPV  Human papillomavirus 
 
ICAM  Intercellular adhesion molecule 
iDC  Immature dendritic cell 
IFN  Interferon  
Ig  Immunoglobulin 
IL  Interleukin 
ISCOM Immune-stimulating complex 
IS  Immunological synapse 
 
KLK  KLKLLLLLKLK 
KPK  KLKLLPLLKPK 
 
LC  Langerhans cell 
LFA  Leucocyte function associated antigen 
LN  Lymph node 
LPS  Lipopolysaccharide 
LRR  Leucine rich repeat 
 
MIIC  MHC II-enriched compartment 
MHC  Major histocompatibility complex 
mDC  Myeloid dendritic cell 
moDC  Monocyte-derived dendritic cell 
MVB  Multivesicular bodies 
MyD88  
 
NMR  Nuclear magnetic resonance 
NLR  Nucleotide domain leucine-rich repeat containing receptor 
NKC  Natural killer cell 
NKTC  Natural killer T cell 
 
 ODN  Oligodoxynucleotides 
ODN1a Oligo-(dIdC)13 
 
PAMP  Pathogen associated molecular pattern 
PBFI  Potassium sensitive benzofuran isopthalate 
PC  Phosphatidylcholin 
pDC  Plasmacytoid dendritic cell 
PE  Phosphatidylethanolamine 
PI  Phosphatidylinositol 
PKC  Protein kinase C 
POPC  1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
POPG  1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol 
PRR  Pattern recognition receptor 
PS  Phosphatidylserine 
 
RE  Recycling endosome 
RNA  Ribonucleic-acid 
 
SCF  Stem cell factor 
SM  Sphingomyelin 
 
TAP  Transporter associated with antigen processing 
TCR  T-cell receptor 
TFE  2,2,2-trifluoroethanol 
TfR  Transferrin receptor 
TGN  Trans golgi network 
TLR  Toll like receptor 
TMA-DPH trimethylammonium-DPH  
TNF  Tumor necrosis factor 
 
VLP  Virus-like particle 
VPS  Vacuolar protein sorting 
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